腎と透析　Vol.65　増刊　血液浄化療法　2009

総論

P.16 掲載の参考文献

1) Kollf WJ, Berk HThJ : The artificial kidney : a dialyser with a great area. Acta Med Scand 117 : 121-134, 1944

 

2) Survey by Fresenius Medical Care Co., Germany

 

3) Saito A : Kidney tissue engineering. Tissue Engineering using Ceramics and Polymers, Boccaccini AR, Gough JE (eds), pp421-444, Woodhead Publishing Limited, Cambridge, 2007

 

P.21 掲載の参考文献

1) Drukker W : Hemodialysis : A historical review. Replacement of Renal Function by Dialysis, Drukker W, Person FM, Maher J (eds), pp3-52, Martinus Nijhoff Publishers, Boston/The Hague/Dordreht/Lancaster, 1983

 

2) 森井浩世, 井上隆, 田畑勉, 他 : 透析医学の歴史. 透析医学の分化と技術, 森井浩世編, pp28-38, 医薬ジャーナル社, 大阪市, 1999

 

3) 太田和夫 : 透析医療の歴史-先人の軌跡をたどって, メディカ出版, 東京, 2008

 

4) 青池郁夫 : 血液透析の歩みと現在の問題点. 透析療法ネクスト 1 : 秋葉隆, 秋澤忠男編, pp31-40, 医学図書出版, 東京, 2001

 

5) 太田和夫編 : 透析療法の歴史. 人工腎臓の実際 (改訂第5版), pp1-7. 南江堂, 東京, 2005

 

P.28 掲載の参考文献

1) Uchino S, Kellum JA, Bellomo R, Doig GS, et al : Acute Renal Failure in Critically Ill Patients : A Multinational, Multicenter Study. JAMA 294 : 813-818, 2005

PubMed

2) 滝川康裕, 佐藤彰宏, 遠藤龍人, 鈴木一幸 : 劇症肝不全の全国統計. 肝胆膵 51 (1) : 7-15, 2005

Medical*Online

3) 日本アフェレシス学会学術委員会 : アフェレシスの現状 (2002年分調査結果より). 日本アフェレシス学会雑誌 24 (1) : 110-116, 2005

 

4) 日本透析医学会統計調査委員会, 同小委員会 : わが国の慢性透析療法の現況 (2006年12月31日現在). 透析会誌 41 (1) : 1-28, 2008

 

5) 中井滋 : 透析患者の悪性腫瘍 : 透析患者に多発するのか : 日本-日本透析医学会統計調査から. 臨牀透析 21 (4) : 11-16, 2005

 

6) 日本透析医学会統計調査委員会, 日本透析医学会小委員会 : わが国の慢性透析療法の現況 (2005年12月31日現在). 透析会誌 40 (1) : 1-30, 2007

 

血液浄化総論

P.38 掲載の参考文献

1) 峰島三千男 : 作用原理と評価方法. Clinical Engineering 1 : 428-433, 1990

 

2) Kedem O, Katchalsky A : Thermodynamic analysis of the permeability of biological membranes to non-electrolytes. Biochim Biophys Acta 27 : 229, 1958

PubMed

3) 酒井清孝 : 人工透析膜の設計-透析カイネティックスより-. 膜 14 : 31-44, 1989

 

4) Colton CK, Lowrie EG : Chapter 47, Hemodialysis : Physical principles and technical considerations. The Kidney (2nd ed), Volume II, Brenner BM, Rector FC Jr (eds), pp2476-2489, WB Saunders, Philadelphia・London・Toronto, 1981

 

5) Kimura S, Sourirajan S : Analysis of data in reverse osmosis with porous cellulose acetate membranes used. AIChE J 13 : 497, 1967

 

6) 峰島三千男 : 分離器の性能評価, 日本アフェレシス学会技術マニュアル 2001. 日本アフェレシス学会雑誌 20 : 233-238, 2001

 

7) 柳井弘 : 固定層 (移動層) 吸着操作の設計と経済的評価. 吸着材・吸着操作の設計-その具体的プロセスと経済性-, pp140-258, 技報堂出版, 東京, 1982

 

P.44 掲載の参考文献

1) 日本医師会Web, 医療従事者ための医療安全対策マニュアル http://www.med.or.jp/anzen/manual/menu.html

 

2) 医療安全対策室, 医療安全管理体制, 東京女子医科大学学内 Web (非一般公開)

 

3) 独立行政法人医薬品医療機器総合機構, 安全性情報報告書安全性情報報告書 http://www.info.pmda.go.jp/info/houkoku.html

 

4) http://www.fda.gov/medwAtch/safety/2008/safety08.htm#HeparinInj2

 

P.48 掲載の参考文献

1) 日本透析医学会 : 日本透析医学会透析医学用語集. 透析会誌 40 : 957-1023, 2007

 

2) 日本急性血液浄化学会 : 「急性血液浄化法に関する名称・用語」試案. http://jsbpcc.umin.jp/06.htm

 

3) 日本アフェレシス学会 : アフェレシス技術マニュアル. 日本アフェレシス学会雑誌 26 : 1-197, 2007

 

4) Daugirdas JT, et al ed : Handbook of dialysis 4th ed, Wolters Kluwer. 2007

 

血液浄化各論

P.54 掲載の参考文献

1) 日本透析医学会統計調査委員会 : わが国の慢性透析療法の現況 (2006年12月31日現在), 2007

 

2) 斎藤明, 高木豊巳, 鄭大基, 他 : Protein-losing hemofilterの臨床と濾過液中の中・大分子量物質の分析. 人工臓器 10 : 907-910, 1981

 

3) 水口潤 : HDF療法の最前線, 第47回日本透析医学会ランチョンセミナー, 2002

 

4) 日本透析医学会統計調査委員会 : わが国の慢性透析療法の現況 (1999年12月31日現在), 2000

 

5) 日本透析医学会統計調査委員会 : わが国の慢性透析療法の現況 (1997年12月31日現在), 1998

 

6) Koda Y, Nishi S, Miyazaki S, et al : Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 52 : 1096-1101, 1997

PubMed

P.58 掲載の参考文献

1) わが国の慢性透析療法の現況 (2001年12月31日現在). pp559-560, 日本透析医学会, 2002

 

2) Eknoyan G, Beck G, Cheung AK, et al : Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347 : 2010-2019, 2002

PubMed

3) McClellan WM, Soucie JM, Flanders WD : Mortality in end-stage renal disease is associated with facility-to-facility differences in adequacy of hemodialysis. J Am Soc Nephrol 9 : 1940-1947, 1998

PubMed

4) Chertow GM, Owen WF, Lazarus JM, et al : Exploring the reverse J-shaped curve between urea reduction ratio and mortality. Kidney Int 56 : 1872-1878, 1999

 

5) Li Z, Lew NL, Lazarus JM, Lowrie EG : Comparing the urea reduction ratio and the urea product as outcome-based measures of hemodialysis dose. Am J Kidney Dis 35 : 598-605, 2000

 

6) Salahudeen AK, Dykes P, May W : Risk factors for higher mortality at the highest Ievels of spKt/V in haemodialysis patients. Nephrol Dial Transplant 18 : 1339-1344, 2003

 

7) わが国の慢性透析療法の現況 (2001年12月31日現在). pp562-563, 日本透析医学会, 2002

 

P.68 掲載の参考文献

1) Bab AL, et al : The genesis of the square meter-hour hypothesis. Trans Am Soc Artif Intern Organs 17 : 81-91, 1971

 

2) Gejyo F, et al : A new form of amyloid protein associated with chronic hemodialysis was identified as β2-microglobulin. Biochem Biophys Res Commun 129 : 701-706, 1985

 

3) 越川昭三 : ダイアライザ開発の歴史. 臨牀透析 16 : 843-856, 2000

 

4) Vanholder R, et al : Review on uremic toxins : classification, concentration, and interindividual variability. Kidney Int 63 : 1934-1943

 

5) Aoike I : Clinical significance of protein adsorbable membranes-long-term clinical effects and analysis using a proteomic technique. Nephrol Dial Transplant 22 (suppl 5) : v13-19, 2007

 

6) 秋葉隆, 他 : 透析液水質基準と血液浄化器性能評価基準 2008. 透析会誌 41 : 159-168, 2008

 

7) Fukuda M, et al : Anisotropic differences in solute transfer rate through asymmetric membranes for blood purification accompanied by filtration. Biochem Eng J 2 : 127-136, 1998

 

8) 秋澤忠男, 他 : 生体適合性の考え方と変遷. 腎と透析 45 別冊ハイパフォーマンスメンブレン '98 : 8-11, 1998

 

9) Panichi, V, et al : The link of biocompatibility to cytokine production. Kidney Int 76 (suppl) : S96-103, 2000

PubMed

10) 佐中孜 : 活性酸素仮説. 透析会誌 24 : 273-287, 1991

 

11) Hayama M, et al : Nanoscopic behavior of polyvinylpyrrolidone particles on polysulfone/polyvinylpyrrolidone film. Biomaterials 25 : 1019-1028, 2004

PubMed

P.75 掲載の参考文献

1) 福田誠, 吉田一 : QOLの向上をめざした透析器開発への取り組みと今後の展開. 腎と透析 61 別冊ハイパフォーマンスメンブレン '06 : 12-18, 2006

 

2) 清水英範 : フレゼニウスポリスルフォン(R) 膜 : 開発の歴史と現況および今後の課題. 腎と透析 61 別冊ハイパフォーマンスメンブレン '06 : 27-32, 2006

 

3) Sakai Y, Wada S, Matsumoto H, et al : Nondestructive evaluation of blood flow in a dialyzer using X-ray computed tomography. J Artf Organs 6 : 197-204, 2003

 

4) Hardy PA, Poh C, Liao Z, Clark W, et al : The use of magnetic resonance imaging to measure the local ultrafiltration rate in hemodialyzers. J Membrane Science 5256 : 1-11, 2002

 

5) Poh C, Hardy PA, Liao Z, Huang Z, et al : Effect of Spacer Yarns on the Dialysate Flow Distribution of Hemodialyzers : A Magnetic Resonance Imaging Study. ASAIO J : 440-448, 2003

PubMed

6) Fukuda M. Miyazaki M, Uezumi S, Yoshida M : Design and Assessment of a New APS Dialyzer (APS-SA Series), J Artif Organs 9 (3) : 192-198, 2006

 

7) Yamamoto K, Matsukawa H, Yakushiji T, Fukuda M, et al : Technical evaluation of dialysate flow in a newly designed dialyzer. ASAIO J 53 : 36-40, 2007

 

P.79 掲載の参考文献

1) 日本透析医学会 : 慢性血液透析用バスキュラーアクセスの作製および修復に関するガイドライン. 透析会誌 38 : 1502-1508, 2005

 

2) Brescia MJ, Cimino JE, Hurwich BJ : Chronic haemodialysis using vein puncture and a surgically created arteriovenous fistula. N Engl J Med 275 : 1089-1092, 1966

 

3) Harder FT, Haenel AF : Haemodialyse-die arterio-venose Fistel distal des Hand-gelenkes. Chirurg 48 : 719-722, 1977

 

4) 久木田和丘, 増子佳弘, 有倉潤, 他 : タバチエール内シャントは内シャント寿命を延長するか. 腎と透析 51 別冊アクセス 2001 ; 87-89, 2001

 

5) Konner K : Primary vascular access in diabetic patients : an audit. Nephrol Dial Transplant 17 : 1057-1062, 2002

 

P.83 掲載の参考文献

1) NKF-K/DOQI Clinical Practice Guidelines for Vascular Access : update 2000. Am J Kidney Dis 37 (suppl 1) : S137-181, 2001

 

2) 阿岸鉄三, 春口洋昭 : 慢性血液透析患者用ブラッドアクセスの現況～全国透析施設集計例の分析を中心に～. 臨牀透析 16 : 1447-1452, 2000

 

3) 太田和夫, 他 : テルモ社製透析用人工血管 (GRASIL(R)) の臨床使用-長期成績-. 透析会誌 39 : 1395-1401, 2006

 

4) Lazarides MK, Staramos DN, Panagopoulos GN, et al : Indications for surgical treatment of angioaccess-induced arterial "steal". J Am Coll Surg 187 : 442-446, 1998

 

P.86 掲載の参考文献

1) 社団法人日本透析医学会「慢性血液透析用バスキュラーアクセスの作製および修復に関するガイドライン」. 透析会誌 38 : 1491-1551, 2005

 

2) 菊池洋, 甲斐浩治, 望月貞二, 他 : ダブルルーメンカテーテルの右内頸静脈留置症例の問題点-鎖骨下静脈大腿静脈留置時のカテーテル管理をも含めての対比より-. 透析会誌 30 : 1303-1307. 1997

 

3) National kidney Foundation : K/DOQI clinical practice guidelines for vascular access : update 2000. Am J Kidney Dis 37 (suppl 1) : S137-181, 2001

 

4) Yu VL, Goetz A, Wagener M, et al : Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. N Engl J Med 315 : 91-96. 1986

PubMed

5) Twardowski ZJ, Van Stone JC, Haynie JD : All currently used measurements of recirculation in blood access by chemical methods are flawed due to intradialytic disequilibrium or recirculation at low flow. Am J Kidney Dis 22 : 24-29. 1998

PubMed

P.90 掲載の参考文献

1) 日本透析医学会 : 慢性血液透析用バスキュラーアクセスの作製および修復に関するガイドライン. 透析会誌 38 : 1491-1551, 2005

 

2) 金平泰, 高杉昌幸, 中本雅彦 : ブラッドアクセス設置による循環動態への影響. 臨牀透析 9 : 47-54, 2000

 

3) 室谷典義 : Vascular accessと血行動態透析患者の循環器疾患に対する最新治療, 小坂真一編, pp46-54, 南江堂, 東京, 2006

 

P.94 掲載の参考文献

1) 斎藤明 : 治療法 酢酸フリー透析液. Annual review腎臓, pp247-251, 中外医学社, 東京, 2008

 

P.101 掲載の参考文献

1) Zusman RM, Rubin RH, Cato AE, et al : Hemodialysis using Prostacyclin instead of heparin as the sole antithrombotic agent. N Engl J Med 304 : 934-939, 1981

PubMed

2) Davenport A, Lai KN, Hertel J, et al : Anticoagulation. Handbook of dialysis 4th ed, Daugirdas JT, Blake PG, Ing TS (eds), pp204-218, Lippincott Williams & Wilkins, Philadelphia, 2007

 

3) Sonawane S, Kasbekar N, Berns JS : The safety of heparins in end-stage renal disease. Semin Dial 19 : 305-310, 2006

 

4) 越川昭三, 秋沢忠男, 金森直明, 他 : 低分子ヘパリンLHG-500の血液透析用抗凝固薬としての効果-透析開始時単回投与法による検討. 腎と透析 29 : 817-835, 1990

 

5) 金森直明, 衣笠えり子, 関口高, 他 : 血液透析用抗凝固薬低分子ヘパリンのbed side monitor法としての全血Xa凝固時間の有用性. 腎と透析 28 : 965-969, 1990

 

6) Lim W, Cook DJ, Crowther MA : Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure : a meta-analysis of randomized trials. J Am Soc Nephrol 15 : 3192-3206, 2004

PubMed

7) Warkentin TE, Levine MN, Hirsh J, et al : Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 332 : 1330-1335, 1995

PubMed

8) Akizawa T, Koshikawa S, Ota K, et al : Nafamostat Mesilate : A regional anticoagulant for hemodialysis in patient at high risk for bleeding. Nephron 64 : 376-381, 1993

PubMed

9) Yeh RW, Jang IK : Argatroban : Update. Am Heart J 151 : 1131-1138, 2006

PubMed

10) Murray PT, Reddy BV, Grossman EJ, et al : A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease. Kidney Int 66 : 2446-2453, 2004

PubMed

11) Fischer KG : Essentials of anticoagulation in hemodialysis. Hemodial Int 11 : 178-189, 2007

PubMed

P.104 掲載の参考文献

1) 菅野有造 : 個人用透析装置. 臨牀透析 (増刊) : 858-866, 2007

 

2) 東レメディカル : TR-3000Sメンテナンスマニュアル

 

3) ニプロ : NCU-12マニュアル

 

4) 日機装 : DBB-73マニュアル

 

P.108 掲載の参考文献

1) 「医療機器に係わる安全管理のための体制確保に係わる運用上の留意点」～運用のための Q&A集～ : http://www.jacet.or.jp/10topics/Q&A5b.pdf

 

P.115 掲載の参考文献

1) 「透析装置等安全基準ガイドライン」に関する調査票. 2008. 02. 22

 

P.118 掲載の参考文献

1) 秋葉隆, 他 : 透析液水質基準と血液浄化器性能評価基準 2008. 透析会誌 41 (3) : 150-167, 2008

 

P.123 掲載の参考文献

1) 斎藤 明. 秋澤忠男, 佐藤隆, 山木万里朗, 他 : 酢酸フリー透析剤SZ-D21多施設共同比較臨床試験 (第III相試験). 診療と新薬 44 : 260-278, 2007

 

2) 芝本隆, 谷口昌弘, 中川成之輔, 阿部富弥 : 重炭酸注入法の相違によるイオン化カルシウム濃度への影響. 透析会誌 14 : 193-201, 1981

 

3) 菅野有造, 芝本隆 : 処方透析. 臨牀透析 23 : 93-98, 2007

 

4) 水田泰一, 西山昌慶 : プロセス・アナリティカル・テクノロジーの解説. Pharm Tech Japan 18 : 13-29, 2002

 

P.127 掲載の参考文献

1) Clark WR, Turk JE, Kraus MA, Gao D : Dose determinants in continuous renal replacement therapy. Artif Organs 27 : 815-820, 2003

PubMed

P.130 掲載の参考文献

1) 川口良人, 斎藤明, 内藤秀宗, 金成泰, 他 : 血液浄化の新たな機能分類-血液浄化法, 適応と対応. 透析会誌 32 : 1465-1469, 1999

 

2) 川西秀樹, 峰島三千男, 竹沢真吾. 政金生人, 他 : 新たな透析液水質基準と血液浄化器の機能分類. 透析会誌 38 : 149-154, 2005

 

3) 池田裕 : 血液浄化器. 臨牀透析 (増刊号) : 31-34, 2007

 

4) 金成泰 : 大量液置換血液浄化法. 血液浄化療法の指針-新しい方向性, 斎藤明, 内藤秀宗編, pp55-76, 日本メディカルセンター, 東京, 1997

 

P.134 掲載の参考文献

1) Henderson LW, Livoti LG. et al : Clinical experience with hemodiafiltration. Trans Am Soc Artif Intern Organs 19 : 119, 1973

 

2) Quellhorst E, Ringer J, et al : Treatment of chronic uremia by an ultra-filtration kidney-first clinical experience. Proc Eur Dial Transplant Assoc 13 : 314, 1976

 

3) 小池正 : 人工腎臓の実際. 内科 20 : 671-680, 1967

 

4) 越川昭二, 三村信英, 平澤由平, 他 : Hemodiafiltrationの臨床的評価-多施設共同研究の成果報告. 腎と透析 11 : 665-675, 1981

 

5) 田中修一, 他 : Fail-softの考えより生まれたサブラッドBSの開発. 医薬品研究 Pharm Regul Sci 36 (4) : 194-206, 2005

 

P.142 掲載の参考文献

1) Sakai K : Artificial Kidney Engineering-Dialysis Membrane and Dialyzer for Blood Purification-, J Chem Eng Jpn 30 : 587-899, 1997

 

P.146 掲載の参考文献

1) 金成泰, 山本千恵子, 石原則幸, 他 : HDFの臨床効果-HDF研究会アンケート調査結果より-. 腎と透析 61 別冊HDF療法 '06 : 23-28, 2006

 

2) 田岡正宏 : On-line HDFとPush & pull HDF. 臨牀透析 24 (9) : 103-108, 2008

 

3) 秋葉隆, 川西秀樹, 峰島三千男, 他 : 透析液水質基準と血液浄化器性能評価基準. 透析会誌 41 (3) : 159-167, 2008

 

4) 峰島三千男 : 濾過型血液浄化器の溶質除去特性に関する研究. 東女医大誌 66 : 283-291, 1996

 

5) 小野裕明, 川西秀樹, 平ひとみ, 他 : 前希釈on-line HDF, 後希釈on-line HDFの除去性能. 腎と透析 55 別冊HDF療法 '03 : 142-144, 2003

 

6) Nakai S, Iseki K, Tabei K, et al : Outcomes of hemodiafiltration based on Japanese dialysis patient registry. Am J Kidney Dis 38 (4 suppl 1) : S212-216, 2001

 

7) Donauer J, Schweiger C, Rumberger B, et al : Reduction of hypotensive side effects during online-haemodiafiltration and low temperature haemodialysis. Nephrol Dial Transplant 18 : 1616-1622, 2003

PubMed

P.151 掲載の参考文献

1) Usuda M, Shinzato T, Sezaki R, Kawanishi A, et al : New simultaneous HF and HD with no infusion fluid. Trans Am Soc Artif Organs 28 : 24-27, 1982

PubMed

2) Shinzato T, Fujisawa K, Nakai S. Miwa H, et al : Newly developed economical and efficient push/pull hemodiafiltration. Effective Hemodiafiltration, New Methods, Contrib Nephrol vol. 108, Maeda K, Shinzato T (eds), pp79-86, Basel, Karger, 1994

 

3) 血液浄化療法の機能・効率に関する学術小委員会 : 透析液水質基準と血液浄化器性能評価基準 2008. 透析会誌 41 : 159-168, 2008

 

4) Dellanna F, Wuepper A, Baldamus CA : Internal filtration-advantage in haemodialysis? Nephrol Dial Transplant 11 (suppl 2) : 83-86, 1996

 

P.156 掲載の参考文献

1) Zucchelli P, Santoro A, et al : Acetate-free Biofiltration (AFBF) : An attractive alternative to bicarbonate dialysis (BD). Blood Purif 5 : 319, 1987

 

2) Van Stone JC, Mitchell A : Hemodialysis with base free dialysate. Proc Clin Dial Transplant Forum 10 : 268-270, 1980

PubMed

3) Henderson LW, Koch KM, Dinarello CA, et al : Hemodialysis hypotensin : The interleukin hypothesis. Blood Purif 1 : 3, 1983

 

4) Kuragano T, Kuno T, et al : The effect of acetate free biofiltration on oxidative stress on DNA and carbonyl stress of human blood. Nephrol Dial Transplant 18 (suppl 4) : 191, 2003

 

5) 久野勉 : Acetate free Biofiltratonの実際. 腎と透析 63 別冊HDF療法 '07 : 80-82, 2007

 

P.162 掲載の参考文献

1) 日本透析医学会 : わが国の慢性透析療法の現況 (2006. 12. 31現在)

 

2) 佐藤威, 斎藤明, 内藤秀宗, 他 : 報告各種の血液浄化法の機能と適応-血液浄化器の性能評価法と機能分類. 透析会誌 29 (8) : 1231-1245, 1996

 

3) 川口良人, 斎藤明, 内藤秀宗. 他 : 血液浄化器の新たな機能分類-血液浄化法, 適応との対応. 透析会誌 32 (12) : 1465-1469, 1999

 

4) 川西秀樹, 峰島三千男, 竹澤真吾, 他 : 新たな透析液水質基準と血液浄化器の機能分類-第49回日本透析医学会コンセンサスカンファレンス「血液浄化器の新分類-内部濾過と透析液水質による再評価」より-. 透析会誌 38 (2) : 149-154, 2005

 

5) 丹下佳洋, 三宅新一, 松本和広, 他 : APS-21Eを凌駕するダイアライザーの探索. 中国腎不全研究会誌 (CJRF) 16 : 285-286, 2007

 

6) Sakai K, Takesawa S, Mimura R, et al : Structural analysis of hollow fiber dialysis membranes for clinical use. J Chem Eng Jpn 20 : 351-356, 1986

 

P.168 掲載の参考文献

1) 佐藤宜伯 : 血液浄化機器 2007. 臨牀透析 23 (7) : 87-93, 2007

 

2) 川西秀樹 : 血液浄化療法. 課題と展望 血液濾過・血液透析濾過療法の現況と課題. 医学のあゆみ 214 (13) : 1046-1050, 2005

 

3) 秋葉隆 : 人工臓器 最近の進歩 人工腎臓. 人工臓器 34 (3) : 156-158, 2005

 

P.173 掲載の参考文献

1) Hirasawa H, Oda S, Matsuda K : Continuous hemodiafiltration with cytokine-adsorbing hemofilter in the treatment of severe sepsis and septic shock. Contrib Nephrol 156 : 365-370, 2007

PubMed

2) Oda S, Hirasawa H, Shiga H, Nakanishi K, et al : Continuous hemofiltration/hemodiafiltration in critical care. Ther Apher 6 (3) : 193-198, 2002

PubMed

3) Ronco C, Cruz D, Bellomo R : Continuous renal replacement in critical illness. Contrib Nephrol 156 : 309-319, 2007

PubMed

4) Luyckx VA, Bonventre JV : Dose of dialysis in acute renal failure. Semin Dial 17 : 30-36, 2004

PubMed

5) Ronco C, Ricci Z, Bellomo R : Importance of increased ultrafiltration volume and impact on mortality : sepsis and cytokine story and the role of continuous veno-vernous haemofiltration. Curr Opin Nephrol Hypertens 10 : 755-761, 2001

 

P.178 掲載の参考文献

1) 塚本功, 山下芳久 : 持続緩徐式血液濾過器. 臨牀透析 23 : 815-819, 2007

 

2) 松田兼一, 他 : 各種操作条件における持続的血液濾過透析 (CHDF) の物質除去性能の検討-小分子量物質およびcytokine除去効率の検討を中心に-. ICUとCCU 26 (別冊) : S66-S68, 2002

Medical*Online

3) 土田健司, 他 : 各種透析膜のエンドトキシンの吸着性と通過性の比較. 腎と透析 47 別冊HDF療法 '99 : 65-69, 1999

 

4) 池田太寛幸, 松金隆夫, 東仲宣 : 各種透析膜でのフサン(R) (メシル酸ナファモスタット) 吸着性の検討. 腎と透析 53 別冊ハイパフォーマンスメンブレン '02 : 71-73, 2002

 

5) 仲松晋也, 他 : 急性血液浄化に用いられる急性血液浄化機器と透析置換液開発の要件 CHDF施行時のhemofilterに期待される要件. ICUとCCU 31 (別冊) : S115-S119, 2007

 

P.184 掲載の参考文献

1) 高橋良光, 大浜和也, 菅野義彦, 他 : 小児CHDF用bedside console. 小児外科 40 (3) : 275-279, 2008

Medical*Online

2) 山下芳久 : 持続緩徐式血液浄化装置. 日本アフェレシス学会雑誌 26 (1) : 155-168, 2007

 

3) 塚本功, 山下芳久 : 持続的血液浄化装置. 臨牀透析 23 (7) : 153-157, 2007

 

4) 大石義英 : 急性血液浄化療法専用装置・システムの変遷と最近の動向. Clinical Engineering 17 (9) : 951-957, 2006

 

P.187 掲載の参考文献

1) Paolo ND, Sacchi G : The normal Peritoneum. Atlas of Peritoneal Histology. Perit Dial Int 20 (suppl 3) : S9-S36, 2000

 

2) Simonescu M, Simonescu N : Organization of cell junctions in peritoneal mesothelium. J Cell Biol 74 : 98-110, 1977

 

3) Gotloib L, Shostak A, Bar-Sella P, et al : Fenestrated capillaries in human peritoneal and rabbit diaphragmatic peritoneum. Nephron 41 : 200-202, 1985

 

4) Abott WE, Shea LP : The treatment of temporary renal insufficiency (uremia) by peritoneal lavafe. Am Med Sci 211 : 312-315, 1946

 

5) Popovich RP : The definition of a novel portable/wearable equilibrium peritoneal dialysis technique. Abstr Amer Soc Artif Intern Oragans 5 : 64-67, 1976

 

P.192 掲載の参考文献

1) Popovich RP, Moncrief JW, Dechard JF, Bomer JB, et al : The definition of a novel portable/wearable equilibrium peritoneal dialysis technique. Abstr Amer Soc Artif Intern Organs 5 : 64, 1976

 

2) Twardowski ZJ, Nolph KD, Prowant BF, Ryan LP, et al : Peritoneal equilibration test. Perit Dial Bull 7 : 138-147, 1987

 

3) Henderson LW, Nolph KD : Altered permeability of the peritoneal membrane after using hypertonic peritoneal dialysis nuid. J Clin Invest 48 : 992-1000, 1969

 

4) Babb AL, Johansen PJ, Strand MJ, Tenckhoff H, et al : Bi-directional permeability of the human peritoneum to middle molecules. Proc Eur Dial Transplant Assoc 10 : 247-262, 1973

PubMed

5) Garred LJ, Canaud B, Farell PC : A simple kinetic model for assessing peritoneal mass transfer in chronic continuous ambulatory peritoneal dialysis. ASAIO J 6 : 131-137, 1983

 

6) 山下明泰, 濱田浩幸 : 腹膜透過能の新しい簡易評価式の導出. 透析会誌 31 : 183-189, 1998

 

7) Popovich RP, Pyle WK, Bomer JB, Moncrief JW : Peritoneal dialysis-Chronic replacement of kidney function. Amer Inst Chem Eng Symp Series 18775 : 31-45, 1979

 

8) Rippe B : A three-pore model of peritoneal transport. Perit Dial Int 13 (suppl 2) : S35-S38, 1993

 

9) Yamashita AC, Ishizaki M, Nakamoto M, Kawanishi H, et al : Re-evaluation of adequate dose in Japanese PD patients. Adv Perit Dial 19 : 103-105, 2003

 

P.196 掲載の参考文献

1) Twardowski ZI, Nolph KD, Kahnna R, Prowant BF, et al : The need for a "Swan Neck" permanently bent, arcuate peritoneal dialysis catheter. Perit Dial Bull 5 : 219-223, 1985

 

2) 山川正人, 日並加保 : 胸部出口法におけるウルトラロングカテーテルの有用性. 腎と透析 63 別冊腹膜透析 2007 : 128-130, 2007

 

3) 窪田実, 石黒望, 濱田千江子, 他 : バスタブカテーテル (presternal catheter) の成績. 腎と透析 49 : 59-63, 2000

 

4) 窪田実. 都筑優子, 西澤欣子, 他 : 上腹部カテーテル出口 (upper abdominal exit : UAE) はさまざまな利点を有する. 腎と透析 61 別冊腹膜透析 2006 : 393-394, 2006

 

5) Kubota M, Kanazawa M, Takahashi Y, et al : Plantation of presternal catheter using Moncrief technique : Aiming for fewer catheter-related complications. Perit Dial Int 21 : S205-208, 2001

 

P.199 掲載の参考文献

1) Gotloib L, Wajsbrot V, Shostak A : Icodextrin-induced lipid peroxidation disrupts the mesothelial cell cycle engine. Free Radic Biol Med 15 : 419-428, 2003

 

2) Kawanishi H, Hashimoto Y, Nakamoto H, et al : Combination therapy with peritoneal dialysis and hemodialysis. Perit Dial Int 26 : 150-154, 2006

PubMed

3) Williams JD, et al on behalf of the Euro Balance Trial Group : The Euro-Balance Trial : the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 66 : 408-418, 2004

 

4) Lee HY, Park HC, Seo BJ, et al : Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance). Perit Dial Int 25 : 248-255, 2005

PubMed

5) Davies SJ, et al for EAPOS Group : Longitudinal membrane function in functionally anuric patients treated with APD : data from EAPOS on the effects of glucose and icodextrin prescription. Kidney Int 67 : 1609-1615, 2005

PubMed

6) Konings CJ, Schalkwijk CG, van der Sande FM. et al : Influence of icodextrin on plasma and dialysate levels of N (epsilon) - (carboxymethyl) lysine and N (epsilon) - (carboxyethyl) lysine. Perit Dial Int 25 : 591-595, 2005

 

P.203 掲載の参考文献

1) Hoff CM : In vitro biocompatibility performance of physioneal. Kidney Int 64 : S57-74, 2003

 

2) Chan TK, Yung S : Studying the effects of new peritoneal dialysis solutions on the peritoneum. Perit Dial Int 27 : S87-93, 2007

 

3) ter Wee PM : The new peritoneal dialysis solutions : friends only, or foes in part? Nature Clinical Practice Nephrology 3 : 604-612, 2007

PubMed

4) Mclntyre CW : Up date on peritoneal dialysis solutions. Kidney Int 71 : 486-490, 2007

 

5) Higuchi C, Tanihata Y, Nishimura H, Naito T, Sanaka T : Effect of glucose and plasminogen activator inhibitor-1 on collagen metabolism in the peritoneum. Ther Apher Dial 9 : 173-181, 2005

PubMed

P.207 掲載の参考文献

1) 星井桜子 : 低体重児における自動腹膜透析 (APD) サイクラーの問題点. 腹膜透析 '98, pp165-168, 東京医学社, 東京, 1998

 

2) 郭義胤, 児玉志保, 永松理恵 : 低体重児におけるautomated PD. 腎と透析 61 別冊腹膜透析 2006 : 222-223, 2006

 

P.211 掲載の参考文献

1) Kimura S, Sourirajan S : Analysis of data in reverse osmosis with porous cellulose acetate membrane used AIChE J 13 : 497-503, 1967

 

2) Leveque MA : Ann mines 13 : 201, 1928

 

3) Zydney AL, Colton CK : Continuous flow membrane plasmapheresis : Theoretical models for flux and hemolysis prediction. Trans Am Soc Artif Intern Organs 28 : 408-412, 1982

PubMed

4) Eckstein EC, Bailey DG, Shapiro AH : Self-diffusion of particles in a shear flow of a suspension. J Fluid Mech 79 : 191, 1972

 

5) Michaels AS : New separation technique for the CPI. Chem Eng Progress 64 : 31, 1968

 

6) Porter MC : Concentration polarization with membrane ultrafiltration. Ind Eng Chem Prod Res Dev 11 : 234, 1972

 

7) Spiegler KS, Kedem O : Thermodynamics of hyperfiltration (reverse osmosis) : criteria for efficient membrane. Desalination 1 : 311-326, 1966

 

P.218 掲載の参考文献

1) 山根慎滋, 石井祐行, 平澤博之 : 単純血漿交換法 (PE). 日本アフェレシス学会雑誌 26 (1) : 10-18, 2007

 

2) 須磨靖徳 : II. 商品設計. 4. 医療. PLAS-TICS AGE ENCYCLOPEDIA. 進歩編 1990, 進歩編編集委員会編, pp87-96, プラスチック・エイジ, 1989

 

3) Nagano T, Nakazono K, Iwamoto H, Sato T, et al : Comparative Study of Polyethylene Plasma Separator Sterilized by Ethylene Okide and Gamma Rays. Jpn J Apheresis 16 (1) : 297-298, 1997

 

4) 血液浄化膜と生体反応 www.rpm.or.jp/home/yhirai/work/maku3.htm Taketoshi

 

5) 金子岩和 : 血液浄化療法の種類. 血液浄化療法ハンドブック改訂第3版, 透析療法合同専門委員会編, pp6-7, 協同医書出版社, 2004

 

6) 江口圭 : 置換液の使用方法と至適濃度設定法. 日本アフェレシス学会雑誌 26 (1) : 36-47, 2007

 

7) 末岡明伯, 宮原忠司, 高島征助, 高島孝一, 他 : EVAL血漿処理膜の基礎的検討. 人工臓器 13 (2) : 931-934 (1984)

 

8) 末岡明伯, 宮原忠司, 鈴木孝彬, 上田恭典, 他 : 二重濾過血漿成分分離器の濾過性能に及ぼす温度の影響. 人工臓器 15 (3) : 1587-1590, 1986

 

9) 峰島三千男 : 血漿交換の原理-膜型血漿分離-. クリニカルエンジニアリング 19 (4) : 364-368, 2008

 

10) 金野好恵, 江口圭, 峰松祐輔, 他 : 血漿成分分離器Evafiux-5Aの濾過分離特性に及ぼす温度の影響. 日本アフェレシス学会雑誌 25 (2) : 153-158, 2006

 

11) 長野武俊, 岩本ひとみ, 中園和子, 他 : 血漿成分分離器Evaflux-5Aの濾過法の検討. 日本アフェレシス学会雑誌 13 : 74, 1994

 

12) 金野好恵, 江口圭, 天野雄介, 横井良, 他 : 新しい二重膜濾過法 (加温式再循環法) の使用経験-吸着型LDLアフェレシス療法との比較をふまえて-. 日本アフェレシス学会雑誌 22 (1) : 44-50, 2003

 

P.222 掲載の参考文献

1) Agishi T, et al : Double filtration plasmapheresis. Trans Am Soc Artif Intern Organs 26 : 406-410, 1980

PubMed

2) Nakaji S, Yamamoto T : Membranes for therapeutic apheresis. Therapeutic Apheresis 6 : 267-270, 2002

PubMed

3) Hanafusa N, et al : Double filtration plasmapheresis can decrease factor VIII activity. Ther Apher Dial 11 : 165-170, 2007

 

4) Fujiwara K, et al : Double filtration plasmapheresis and interferon combination therapy for chronic hepatitis C patients with genotype 1 and high viral load. Hepatol Res 37 : 701-710, 2007

PubMed

P.228 掲載の参考文献

1) Judson G, Jones A, Kellogg R, et al : Closed continuous-flow centrifuge. Nature 217 : 816-818, 1968

PubMed

2) Corbin F, Cullis HM, Freireich EJ, et al : Development of Apheresis Instrumentation. Apheresis-Principles and Practice, 2nd Ed, pp1-27, AABB press, 2003

 

3) 稲葉頌一 : 血液成分分離装置と血漿交換. 輸血学, 改訂第3版, 遠山博編, pp868-904, 中外医学社, 東京, 2004

 

4) 山家敏彦 : II 技術編. II-2-a. ヘモネティクス社機種. 新版アフェレシスマニュアル-難治疾患の治療革命-, 第2版, クリニカルエンジニアリング別冊, 日本アフェレシス学会編, pp40-43, 秀潤社, 東京, 2004

 

5) 岡部全宏, 篠崎澄子 : II 技術編. II-2-c. ガンプロ社機種. 新版アフェレシスマニュアル-難治疾患の治療革命-, 第2版, クリニカルエンジニアリング別冊, 日本アフェレシス学会編, pp48-53, 秀潤社, 東京, 2004

 

P.233 掲載の参考文献

1) 遠山博, 関口彌 : 血液の保存と管理. 輸血学 改訂第2版, pp81-86, 中外医学社, 東京, 1989

 

2) 桑克彦 : イオン化カルシウムの測定. 検査と技術 19 (2) : 119-124, 1991

 

3) 伊藤経夫, 他 : 末梢血幹細胞採取における心電図監視の必要性を認めた1例. Japanese Journal of Transfusion Medicine 41 (6) : 617-621, 1995

Medical*Online

4) 小島聡, 他 : 健常人PBSCHにおけるカルシウム動態とカルシウム剤の投与効果について. 日本輸血学会雑誌 44 (2) : 165, 1998

Medical*Online

5) 小島聡 : 遠心型血液成分分離装置. 日本アフェレシス学会技術マニュアル 2006, vol 26, No 1, 有限責任中間法人日本アフェレシス学会, 2006

 

P.236 掲載の参考文献

1) Agishi T, Kaneko I, Ota K, et al : Double filtration plasmapheresis. Trans Am Soc Artif Intern Organs 26 : 406-409, 1980

PubMed

2) Nose Y, Malchesky PS, Smith JW : Hybrid artifical organs : Are they really necessary? Artif Organs 4 : 285, 1980

 

3) 佐中孜 : 血漿二重膜濾過法. [新版] アフェレシスマニュアル, 日本アフェレシス学会編, pp69-71, 秀潤社, 東京, 2004

 

4) 黒田重臣 : 血漿冷却濾過法. [新版] アフェレシスマニュアル, 日本アフェレシス学会編, pp72-75, 秀潤社, 東京, 2004

 

5) Horiuchi T, Emura M, Usami M, et al : Thermal Effect of LDL/HDL Separation in Membrane Filtration : Thermofiltration. Trans Am Soc Artif Intern Organs 31 : 704-707, 1985

 

P.244 掲載の参考文献

1) 薬食発0311005号17年3月11日公布 厚生労働省医薬食品局長「薬事法第二条第五項から第七項までの規定により厚生労働大臣が指定する高度管理医療機器, 管理医療機器及び一般医療機器の一部を改正する件 (告示) 及び薬事法第二条第八項の規定により厚生労働大臣が指定する特定保守管理医療機器の一部を改正する件 (告示) の施行について」

 

2) 山家敏彦, 他 : 各種血液浄化療法の回路とその適応. 臨床看護 26 (12) : 1375-1741, 2003

 

3) 山家敏彦 : 血漿交換装置, 血漿吸着装置. 臨牀透析 23 (7) : 143-149, 2007

 

4) 金野好恵, 他 : 新しい二重膜濾過法 (加温再循環法) の使用経験-吸着型LDLアフェレシス療法との比較をふまえて-. 日本アフェレシス学会誌 22 (1) : 44-50, 2003

 

P.249 掲載の参考文献

1) 萩原茂示 : 活性炭吸着のメカニズム. 中毒研究 2 : 11-18, 1989

 

2) 萩原茂示, 山下衛 : 活性炭の臨床応用. 中毒研究 3 : 201-209, 1990

 

3) Yatzidis H, Oreopoulos D, Triantaphyllidis D, Voudiclari S, et al : Treatment of severe barbiturate poisoning. Lancet 1 (7405) : 216-217, 1965

 

4) Chang TMS, Malave N : The development and first clinical use of semipermeable microcapsuies (artificial cells) as a compact artificial kidney. Trans Am Soc Artif Intern Organs 16 : 141-148. 1970

 

5) Chang TMS, Migchelsen M, Coffey JE Stark A : Serum middle molecule levels in uremia during long term intermittent hemoperfusions with the ACAC (coated charcoal) microcapsule artificial kidney. Trans Am Soc Artif Intern Organs 20 : 364-371, 1974

 

6) Gazzard BG, Weston MJ, Murray-Lyon IM, Flax H, et al : Charcoal haemoperfusion in the treatment of fulminant hepatic failure. Lancet 1 (7870) : 1301-1307, 1974

PubMed

7) 伊藤靖, 他 : 血液吸着併用による抗癌剤大量療法に関する基礎実験. 人工臓器 15 : 1613-1615, 1986

 

8) 中島俊秀, 高倉孝一, 古元嘉昭, 中林宣男, 他 : HEMA系ポリマー被覆ビーズ状活性炭を用いた吸着型血液浄化器の基礎研究. 人工臓器 8 : 460-465, 1979

 

P.253 掲載の参考文献

1) Shoji H : Extracorporeal endotoxin removal for the treatment of sepsis : Endotoxin adsorption cartridge (Toraymyxin). Ther Apher & Dial 7 : 108-114, 2003

PubMed

2) Ronco C, Brendolan A, Scabardi M, et al : Blood flow distribution in a poiymyxin coated fibrous bed for endotoxin removal. Effect of a new blood path design. Int J Artif Organs 24 : 167-172, 2001

 

3) Fiore G, Soncini M, Zaupa A, et al : Multi-scale analysis of the Toraymyxin adsorption cartridge. Part II : Computational fluid-dynamic study. Int J Artif Organs 29 : 251-260, 2006

 

4) Vesentini S, Soncini M, Silvestri, et al : Multi-scale analysis of the Toraymyxin adsorption cartridge. Part I : Molecular interaction of polymyxin B with endotoxins. Int J Artif Organs 29 : 239-250, 2006

PubMed

P.258 掲載の参考文献

1) Furuyoshi S, Nakatani M, Taman J, Kutsuki H, et al : New adsorption column (Lixelle) to eliminate β2-microglobulin for direct hemoperfusion. Therapeutic Apheresis 2 : 13-17, 1998

 

2) 中谷勝, 古吉重雄, 高田覚, 谷叙孝 : 透析アミロイドーシス治療用直接血液灌流型吸着器「リクセル」の吸着特性. 人工臓器 27 : 571-577, 1998

 

3) 土田健司, 武本佳昭, 夫 恩澤, 中村敬弘, 他 : SIRS治療におけるサイトカイン吸着療法. エンドトキシン研究 2 新しい展開, 日本エンドトキシン研究会, pp213-219, 菜根出版, 1999

 

4) 下条文武, 川口良人, 原茂子, 中澤了一, 他 : 透析アミロイドーシスに対する直接血液灌流型β2-ミクログロブリン吸着器「リクセル」の臨床効果 : 前向き多施設コントロールβ2-ミクログロブリン吸着器スタディ (βMACS). 腎と透析 46 : 547-560, 1999

 

5) Abe T, Uchita K, Orita H, Kamimura M, et al : Effect of β2-microglobulin adsorption column on dialysis-related amyloidosis. Kidney Int 64 : 1522-1528, 2003

 

6) 日本透析医学会統計調査委員会 : わが国の慢性透析療法の現況 (1999年12月31日現在), pp1002-1003, 日本透析医学会統計調査委員会, 名古屋, 1999

 

7) 原茂子, 乳原善文, 高市憲明, 原重雄 : 透析アミロイドーシスの内科的治療と病勢マーカー. 透析会誌 40 : 1035-1038, 2007

 

P.263 掲載の参考文献

1) Schiff D, Chan G, Poznansky MJ : Bilirubin toxicity in neural cell lines N115 and NBR10A. Pediatric Res 19 : 908-911, 1985

 

2) Mustafa MG, Cowger ML, King TE : Effects of bilirubin on Mitochondrial Reactions. J Biol Chem 244 : 6403-6414, 1969

PubMed

3) Nakaji S, Inukai Y, Takakura K : Deveropment of poly-HEMA coated anion-exchange resin adsorbent for removal of bilirubin in plasma perfusion treatment. Therapuetic Plasmapheresis XII : 211-214, 1993

 

4) Nakaji S, Inukai Y, Takakura K : Deveropment of poly-HEMA coated anion-exchange resin adsorbent for removal of bilirubin in plasma perfusion treatment. Jpn J Artificial organs 22 : 190-193, 1993

 

5) Kabutan K, Kosaka F, Mizobuchi S, et al : Comparison of an anion-exchange resin with an uncoated powdered charcoal column in treatment by plasma perfusion. Therapeutic Plasmapheresis IX : 335-338, 1991

 

6) Kabutan K, Sato N, Yamamoto A, Kosaka F, et al : Clinical evaluation of a new anion-exchange resin column. Jpn J Intensive Care Medicine 15 : 837-842, 1991 (in Japanese)

 

P.268 掲載の参考文献

1) Jimenez-Klingberg C, Borberg H : Comparison of protein A-and tryptophan-conjugated polyvinyl alcohol gel columns with an anti-human immunoglobulin antibody adsorber. Current Advances in Therapeutic Plasmapheresis, Yamamoto A, Gurland JH (eds), pp83-93, Churchill Livingstone, London, 1996

 

2) Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, et al : A serum autoantibody marker of neuromyelitis optica : distinction from multiple sclerosis. Lancet 364 : 2106-2112, 2004

PubMed

3) Warabi Y, Matsumoto Y, Hayashi H : Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J Neurol Sci 252 : 57-61, 2007

PubMed

4) 大橋高志. 太田宏平, 清水優子, 大原久仁子, 他 : 視神経脊髄炎 (NMO) における免疫吸着療法の検討. 東京女子医科大学雑誌 78 (extra) : E94-E98, 2008

 

P.272 掲載の参考文献

1) Tani N : Development of selective low-density lipoprotein (LDL) apheresis system : immobilized polyanion as LDL-specific adsorption for LDL apheresis system. Therapeutic Apheresis 4 : 135-141, 2000

PubMed

2) Matsuzaki M, Hiramori K, Imaizumi T, Kitabatake A, et al : Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia. The Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART). J Am Coll Card 40 : 220-227, 2002

 

3) Tsuchida H, Shigematsu H, Ishimaru S, Iwai T, et al : Effect of low-density lipoprotein apheresis on patients with peripheral arterial disease. Peripheral Arterial Disease LDL Apheresis Multicenter Study (P-LAS). Int Angiology 25 : 287-292, 2006

 

4) Muso E, Mune M, Fujii Y, Imai E, et al : Significantly rapid relief from steroid-resistant nephrotic syndrome by LDL apheresis compared with steroid monotherapy. Nephron 89 : 408-415, 2001

PubMed

5) 岩本ひとみ, 中園和子, 永山絵里子, 福成健一, 他 : リポソーバー試行中に発現する臨床症状. 日本アフェレシス学会誌 25 : 63-67, 2006

 

6) 小嶋俊一 : アフェレシス治療の生体反応と副作用. 腎と透析 60 : 196-201, 2006

 

P.276 掲載の参考文献

1) 竹中良則 : 白血球系細胞除去療法とバイオマテリアル. バイオマテリアル 23 : 224-230, 2005

 

2) 杉憲侑 : 潰瘍性大腸炎治療に期待されるフィルター法白血球除去療法. BIO Clinica 12 : 339-342, 1997

 

3) 竹中良則 : アダカラムを用いた頼粒球・単球除去療法. 日本アフェレシス学会雑誌 22 : 18-26, 2003

 

4) 筏義人 : 人丁臓器材料に対する生体反応. 化学と生物 28 : 552, 1990

 

5) 柏木伸仁 : 顆粒球・単球除去療法と炎症性腸疾患. 消化器の臨床 9 : 215-224, 2006

 

P.284 掲載の参考文献

1) Judson G, Jones A, Kellogg R, et al : Closed continuous-flow centrifuge. Nature 217 : 816-818, 1968

PubMed

2) Corbin F, Cullis HM, Freireich EJ, et al : Development of Apheresis Instrumentation. Apheresis-Principles and Practice, 2nd ed, pp1-27, AABB press, 2003

 

3) 稲葉頌一 : 血液成分分離装置と血漿交換. 輸血学, 改訂第3版, 遠山博編, pp868-904, 中外医学社, 東京, 2004

 

4) 岡部全宏, 篠崎澄子 : II 技術編. II-2-c. ガンプロ社機種. 新版アフェレシスマニュアル-難治疾患の治療革命- 第2版, 日本アフェレシス学会編, クリニカルエンジニアリング別冊, pp48-53, 秀潤社, 2004

 

5) 稲葉頌一 : II 技術編. II-7 末梢血幹細胞採取. 新版アフェレシスマニュアル-難治疾患の治療革命- 第2版, 日本アフェレシス学会編 クリニカルエンジニアリング別冊, pp134-139, 秀潤社, 2004

 

血液浄化法の臨床

P.290 掲載の参考文献

1) Lameire N, Van Biesen W, Vanholder R : Acute renal failure. Lancet 365 : 417-430, 2005

PubMed

2) Liu KD, Himmelfarb J, Paganini E, Ikizler TA, et al : Timing of initiation of dialysis in critically ill patients with acute kidney injury. Clin J Am Soc Nephrol 1 : 915-919, 2006

PubMed

3) Bagshaw SM, Berthiaume LR, Delaney A, Bellomo R : Continuous versus intermittent renal replacement therapy for critically ill patients with acute kidney injury : a meta-analysis. Crit Care Med 36 : 610-617, 2008

PubMed

4) 日本腎臓学会 : 腎疾患患者の生活指導・食事療法に関するガイドライン. 日腎会誌 39 : 1-37, 1997

 

5) Bellomo R, Ronco C, Kellum JA, Mehta RL, et al : Acute Dialysis Quality Initiative workgroup : Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs : the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8 : R204-212, 2004

PubMed

P.294 掲載の参考文献

1) 1993年, 川口良人, 他 : 厚生省透析療法基準検討委員会基準案 (1993年). 日内会誌 89 : 1331-1336, 2000

 

2) The EBPG Expert group : Nephrol Dial Transplant 17 (suppl 7) : 10-12, 2002

 

3) Chan MR, et al : Outcomes in Patients with Chronic Kidney Disease Referred Late to Nephrologists : A Meta-analysis. Am J Med 120 (11) : 1063-1070, 2007

 

4) Lhotta K, et al : Late referral defined by renal function : Association with morbidity and mortality. J Nephrol 16 : 855-861, 2003

PubMed

5) Winkelmayer WC, et al : A Propensity Analysis of Late Versus Early Nephrologist Referral and Mortality on Dialysis. J Am Soc Nephrol 14 (2) : 486-492, 2003

PubMed

P.301 掲載の参考文献

1) Gotch FA, Sargent JA : A mechanistic analysis of the National Cooperative Dialysis Study. Kidney Int 28 : 526-534, 1985

PubMed

2) Lowrie EG, et al : Effect of the hemodialysis prescription of patient morbidity : report from the National Cooperative Dialysis Study. N Engl J Med 305 : 1176-1181, 1981

PubMed

3) Eknoyan G, et al : Hemodialysis (HEMO) Study Group : Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347 : 2010-2019, 2002

 

4) Goodkin DA, et al : Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States : the Dialysis Outcomes and Practice Pattern Study (DOPPS). J Am Soc Nephrol 14 : 3270-3277, 2003

PubMed

5) 日本透析医学会統計調査委員会 : わが国の慢性透析療法の現況 (2001年末現在), 2002

 

6) Saran R, et al : Longer treatment time and slower ultrafiltration in hemodialysis : association with reduced mortality in the DOPPS. Kidney Int 69 : 1222-1228, 2006

PubMed

7) Laurent G, et al : The results of an 8h thrice weekly haemodialysis schedule. Nephrol Dial Transplant 13 (suppl 6) : 125-131, 1998

 

8) 金田浩, 金山史香 : 長時間透析の臨床効果について. 臨牀透析 17 : 1234-1236, 2001

 

9) Marshall MR, et al : Associations of hemodialysis dose and session length with mortality risk in Australian and New Zealand patients. Kidney Int 69 : 1229-1236, 2006

PubMed

10) 川西秀樹, 他 : 新たな透析液水質基準と血液浄化器の機能分類. 透析会誌 38 : 149-154, 2005

 

11) Cheung AK, et al : Effects of high-flux hemodialysis on clinical outcomes : results of the HEMO study. J Am Soc Nephrol 14 : 3251-3263, 2003

PubMed

12) Stenvinkel P, et al : Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 55 : 1899-1911, 1999

PubMed

13) Schiffl H, et al : Ultrapure dialysate fluid slows residual renal function in new dialysis patients. Nephrol Dial Transplant 17 : 1814-1848, 2002

PubMed

14) 山上征二 : 透析液安全基準策定報告「水質及びパイロジェンフィルター評価基準小委員会」. 透析会誌 28 : 1487-1493, 1995

 

15) Ledebo I, Nystrand R : Defining the microbiological quality of dialysis fluid. Artif Organs 23 : 37-43, 1999

PubMed

16) Ketteler M, Giachelli C : Novel insights into vascular calcification. Kidney Int 105 (suppl) : S5-S9, 2006

PubMed

17) Moe SM, et al : Definition, evaluation, and classification of renal osteodytrophy : aposition statement from Kidney Disease : Improving Global Outcomes (KDIGO). Kidney Int 69 : 1945-1953, 2006

 

18) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42 : S1-S201, 2003

PubMed

19) 深川雅史, 他 : 透析患者における二次性副甲状機能亢進症治療ガイドライン. 透析会誌 39 : 1435-1455, 2006

 

20) Besarab A, et al : The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 : 584-590, 1998

PubMed

21) Parfrey PS, et al : Double-blind comparison of fuil and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 16 : 2180-2189, 2005

 

22) Strippoli GFM, et al : Hemoglobin targets for the anemia of chronic kidney disease : a meta-analysis of randomized, controlled trials. J Am Soc Nephrol 15 : 3154-3165, 2004

PubMed

23) Furuland H, et al : A randomized controlled trial of haemoglobin normalization with epoetin alfa in predialysis and dialysis patients. Nephrol Dial Transplant 18 : 353-361, 2003

PubMed

24) Singh AK, et al : CHOIR Investigators : correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 : 2085-2098, 2006

PubMed

25) Drueke TB, et al : CREATE Investigators : normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 : 2071-2084, 2006

PubMed

26) 日本腎臓学会編 : 腎疾患の生活指導・食事療法ガイドライン, 東京医学社, 東京, 1998

 

27) Kidney Disease Outcomes Quality Initiative, National Kidney Foundation : Clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis 35 (suppl 2) : S1-S140, 2000

 

28) Fouque D, et al : EBPG guideline on nutrition. Nephrol Dial Transplant 22 (suppl 2) : ii45-ii87, 2007

 

29) Ikizler TA, et al : Nitrogen balance in hospitalized chronic hemodialysis patients. Kidney Int 56 (suppl) : S53-S56, 1996

 

30) Rao M, et al : Calculated nitrogen balance in hemodialysis patients : influence of protein intake. Kidney Int 58 : 336-345, 2000

PubMed

31) Aparicio M, et al : Nutritional status of haemodialysis patients : aFrench national cooperative study. Nephrol Dial Transplant 14 : 1679-1686, 1999

 

32) Kaysen GA, et al : Longitudinal and cross-sectional effects of C-reactive protein, equilibrated normalized protein catabolic rate, and serum bicarbonate on creatinine and albumin levels in dialysis patients. Am J Kidney Dis 42 : 1200-1211, 2003

PubMed

33) Kloppenburg WD, et al : Effect of prescribing a high protein diet and increasing the dose of dialysis on nutrition in stable chronic haemodialysis patients : a randomized, controlled trial. Nephrol Diai Transplant 19 (5) : 1212-1223, 2004

 

34) Shinaberger CS, et al : Longitudinal associations between dietary protein intake and survival in hemodialysis patients. Am J Kidney Dis 48 (1) : 37-49, 2006

PubMed

P.306 掲載の参考文献

1) 日本透析医学会統計調査委員会 : わが国の慢性透析療法の現況 (2001年12月31日現在), 2002

 

2) Laurent G, Charra B : The results of an 8h thrice weekly haemodialysis schedule. Nephrol Dial Transplant 13 (suppl 6) : 125-131, 1998

 

3) 金田浩, 金田史香 : 長時間透析の臨床効果について. 臨牀透析 17 : 1234-1236, 2001

 

4) Tattersall J, Martin-Malo A, Pedrini L, Basci A, et al : EBPG guideline on dialysis strategies. Nephrol Dial Transplant 22 (suppl 2) : ii5-21, 2007

 

5) Lindsay, RM, Spanner, E : Ahypothesis : The protein catabolic rate is dependent upon the type and amount of treatment in dialyzed uremic patients. Am J Kidney Dis 13 : 382-389, 1989

 

6) 中井滋, 比企能之, 杉山敏 : 透析量ガイドラインのあり方. pp75-85, 透析療法ネクスト VI, 秋葉隆, 秋澤忠男編, pp75-85, 医学図書出版, 東京, 2007

 

7) 日本腎臓学会「腎疾患患者の妊娠に関するガイドライン作成小委員会」 : 透析患者の妊娠. 腎疾患患者の妊娠-診療の手引き, 日本腎臓学会編, pp50-52, 東京医学社, 東京, 2007

 

8) Gangji AS, Windrim R, Gandhi S, Silverman JA, et al : Successful pregnancy with nocturnal hemodialysis. Am J Kidney Dis 44 : 912-916, 2004

PubMed

9) Barua M, Hladunewich M, Keunen J, Pierratos A, et al : Successful Pregnancies on Nocturnal Home Hemodialysis. Clin J Am Soc Nephrol 3 : 392-396, 2008

PubMed

P.311 掲載の参考文献

1) Holt BG, White JJ, Kuthiala A, et al : Sustained low-efficiency daily dialysis with hemofiltration for acute kidney injury in the presence of sepsis. Clin Nephrol 69 (1) : 40-46, 2008

PubMed

2) 岡田一義, 高橋進, 本間徹, 他 : 透析低血圧症に対するGlyceol持続静注と10%NaCl間歇静注併用療法. 透析会誌 23 (3) : 375-378, 1991

 

3) Ramsell JT, Ellis PP, Paterson CA : Intraocular pressure changes during hemodialysis. Am J Ophthalmol 72 : 926-930, 1971

PubMed

4) Kennedy AC, Linton AL, Eaton JC : Urea levels in cerebrospinal fluid after haemodialysis. Lancet 24 (1) : 410-411, 1962

 

5) 川西秀樹, 峯島三千男, 竹澤真吾, 他 : 新たな透析液水質基準と血液浄化器の機能分類-第49回日本透析医学会コンセンサスカンファレンス「血液浄化器の新分類～内部濾過と透析液水質による再評価」より. 透析会誌 38 (2) : 149-154, 2005

 

P.314 掲載の参考文献

1) 三浦明, 鈴木利昭 : 低温透析 [hypothermal dialysis]. 臨牀透析 23 : 141-145, 2007

 

2) 伊丹儀友, 大平整爾 : 低温透析の実際. 臨牀透析 19 : 59-66, 2003

 

3) 千葉栄市, 沢岡憲一, 大村清隆他 : 慢性血液透析症例における低温透析の有効性. 臨床体温 10 : 69-76, 1990

 

4) 山本忠司, 清水元一, 堀内延昭, 他 : 低温度透析液による無症候透析の試み-透析液温度の心循環系への影響-. 透析会誌 17 : 199-203, 1984

 

P.317 掲載の参考文献

1) 田代嗣晴 : 高ナトリウム透析. 臨牀透析 23 (6) : 97-102, 2007

 

2) 古川康隆, 堀川哲彦, 松崎健三 : 高Na透析. 日本臨牀 62 (suppl 5) : 178-181, 2004

 

P.320 掲載の参考文献

1) 青木純一, 上野幸司, 後藤邦広, 久野宗寛, 他 : 血液透析中における持続Ht値測定装置の使用経験. 腎と透析 40 : 136-139, 1996

 

2) Tabei K, Nagashima H, Iimura O, Sakurai T, et al : An index of plasma refilling in hemodialysis patients. Nephron 74 : 266-274, 1996

 

3) 丹波嘉一郎, 田部井薫, 浅野泰, 上野幸司, 他 : 透析中の連続ヘマトクリット測定-除水パターンによる変化-. 透析会誌 29 (suppl) : 804, 1996

 

P.323 掲載の参考文献

1) Lavaud S, Paris B, Maheut H, Randoux C, et al : Assessment of the heparin-binding AN69 ST hemodialysis membrane : II . Clinical studies without heparin administration. ASAIO J 51 : 348-351, 2005

PubMed

2) Blaufox MD, Hampers CL, Merrill JP : Rebound anticoagulation occurring after regional heparinization for hemodialysis. Trans ASAIO 12 : 207-209, 1966

 

3) Akizawa T, Koshikawa S, Ota K, Kazama M, et al : Nafamostat mesilate : a regional anticoagulant for hemodialysis in patients at high risk for bleeding. Nephron 64 : 376-381, 1993

PubMed

4) 上野信一, 谷田部哲夫, 永井弘, 他 : Caフリー透析液を用いた局所抗凝固法における至適クエン酸Naの濃度について. 人工臓器 14 : 72-75, 1985

 

P.329 掲載の参考文献

1) DePalma JR, Pecker EA, Maxwel MH : A new automatic coil dialyzer system for'daily'dialysis. Proc Eur Dial Transplant Assoc 6 : 26-34, 1969

 

2) Ting GO, Kjellstrand C, Freitas T, Carrie BJ, et al : Long-term study of high-comorbidity ESRD patients converted from conventional to short daily hemodialysis. Am J Kidney Dis 42 (5) : 1020-1035, 2003

PubMed

3) Agar JW, Knight RJ, Simmonds RE, Boddington JM, et al : Nocturnal haemodialysis : An Australian cost comparison with conventional satellite haemodialysis. Nephrology 10 (6) : 557-570, 2005

PubMed

4) 越川昭三, 斎藤明, 秋澤忠男, 他 : 連日透析システム (AEK-10) による連日短時間血液透析の有効性と安全性の検討 (多施設共同試験). 透析会誌 36 (12) : 1709-1718, 2003

 

P.335 掲載の参考文献

1) 金田浩, 他 : 21世紀の慢性透析治療法を革命しよう-健常者に限りなく近い長期生存を可能にするために-, 東京医学社, 東京, 2001

 

2) 金田浩, 他 : 続・21世紀の慢性透析治療法を革命しよう「長時間透析と限定自由食のすすめ」-長時間透析は細胞を活性化し高血圧を正常化する-, 東京医学社, 東京, 2005

 

3) 金田浩, 酒井伸一朗, 金田史香, 他 : 長時間透析における高血圧正常化における「循環尿毒素」と「食塩感受性」および「体重増加」の三つの因子の相互関係. 臨牀透析 22 (10) : 1422-1424, 2006

 

4) Charra B, Calemard E, Ruffet M, Chazot C, et al : Survival as an index of adequacy of dialysis. Kidney Int 41 : 1286-1291, 1992

PubMed

P.340 掲載の参考文献

1) 渡邊有三, 中本雅彦, 千葉栄市, 他 : 在宅 (家庭) 血液透析についての提言 透析会誌 31 : 959-965, 1998

 

2) 日本透析医学会統計調査委員会 : わが国の慢性透析療法の現況 (1994年12月現在), pp192-202, 日本透析医学会, 1995

 

3) 小川洋史 : 血液浄化療法の新しいmodality-在宅血液透析. 臨牀透析 25 : 173-179, 2005

 

4) 日本透析医学会統計調査委員会 : わが国の慢性透析療法の現況 (2007年12月31日現在), p2, 日本透析医学会, 2008

 

5) 小関修 : 在宅血液透析普及の問題点と対策-「血液透析患者実態調査報告」にみる在宅血液透析普及の条件. 臨牀透析 20 : 1338-1340, 2004

 

6) 小川洋史 : 在宅血液透析普及の問題点と対策-診療報酬の観点から. 臨牀透析 20 : 1340-1342, 2004

 

7) Raj DD, Charra B, Pierratos A, et al : In search of ideal hemodialysis : Is prolonged frequent dialysis the answer? Am J Kidney Dis 34 : 597-610, 1999

 

8) Pierratos A, Ouwendyk M, Francoeur R, et al : Nocturnal hemodialysis : three-year experience. J Am Soc Nephrol 9 : 859-868, 1998

PubMed

9) Buoncristiani U, Giombini L, Cozzari M, et al : Daily recycled bicarbonate dialysis with polyacrylonitrile. Trans Am Soc Artif Organs 29 : 669-672, 1983

PubMed

P.343 掲載の参考文献

1) 金成泰, 山本千惠子, 石原則幸, 峰島三千男, 他 : HDFの臨床効果-HDF研究会アンケート調査より-. 腎と透析 61 別冊HDF療法 '06 : 23-28, 2006

 

2) 日本透析医学会 : わが国の慢性透析療法の現況 ; 1999年12月31日現在, p1003, 1999

 

3) Locatelli F, Marcelli D, Conte F, et al : Comparison of motality in ESRD patients on convective and diffusive extracorporeal treatments. Kidney Int 55 : 286-293, 1999

 

4) Canaud B, Bragg-Gresham JL, Marshall MR, Desmeules S, et al : Mortality risk for patients receiving hemodiafiltration versus hemodialysis : European results from the DOPPS. Kidney Int 69 : 2087-2093, 2006

PubMed

5) Altieri P, Sorba GB, Bolasco PG, Bostrom M, et al : On-Line Predilution Hemofiltration versus Ultrapure High-Flux Hemodialysis : A Multicenter Prospective Study in 23 Patients. Blood Purif 15 : 169-161, 1997

PubMed

P.347 掲載の参考文献

1) Nakai S, Iseki K, Tabei K, et al : Outcomes of hemodiafiltration based on Japanese dialysis patient registry. Am J Kidney Dis 38 : S212-216 2001

PubMed

2) 甲田豊 : 各種血液浄化法の臨床効果の比較. 血液浄化療法指針-新しい方向性, pp39-54, 日本メディカルセンター, 東京, 1997

 

3) Penne EL, et al : Effect of increased convective clearance by on-line hemodiafiltration on all cause and cardiovascular motality in chronic hemodialsysis patients-the Dutch CONvective TRAnasport STudy (CONTRAST) : rationale and design of a randomised controlled trial

 

4) Pisoni RL, Wikstrom B, Elder SJ, Akizawa T, et al : Pruritus in haemodialysis patients : International results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 21 (12) : 3495-3505, 2006

PubMed

P.351 掲載の参考文献

1) Bongartz LG, Cramer MJ, Doevendans PA, et al : The severe cardiorenal syndrome : 'Guyton revisited' Eur Heart J 26 : 11-17, 2005

PubMed

2) Cotter G, Weissgarten J, Metzkor E, et al : Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure. Clin Pharmacol Ther 62 : 187-193, 1997

PubMed

3) Hasselblad V, Stough WG, Shah MR, et al : Relation between dose of loop diuretics and outcomes in a heart failure population : results of the ESCAPE trial. Eur J Heart Fail 9 : 1064-1069, 2007

 

4) Bart BA, Boyle A, Bank AJ, et al : Ultrafiltration versus usual care for hospitalized patients with heart failure : the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial. J Am Coll Cardiol 46 : 2043-2046, 2005

 

5) Costanzo MR, Guglin ME, Saltzberg MT, et al : Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 49 : 675-683, 2007

PubMed

6) Rogers HL, Marshall J, Bock J, et al : A randomized, controlled trial of the renal effects of ultrafiltration as compared to furosemide in patients with acute decompensated heart failure. J Card Fail 14 : 1-5, 2008

 

P.354 掲載の参考文献

1) Lameire N, Van Biesen W, Vanholder R : Acute renal failure. Lancet 365 : 417-430, 2005

PubMed

2) Bellomo R, Ronco C, Kellum JA, Mehta RL, et al : Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs : the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8 : R204-R212, 2004

PubMed

3) Teehan GS, Liangos O, Jaber BL : Update on dialytic management of acute renal failure. J Intensive Care Med 18 : 130-138, 2003

PubMed

4) Liu KD, Himmelfarb J, Paganini E, Ikizler TA, et al : Timing of initiation of dialysis in critically ill patients with acute kidney injury. Clin J Am Soc Nephrol 1 : 915-919, 2006

PubMed

P.359 掲載の参考文献

1) 急性膵炎の診療ガイドライン作成委員会編 : エビデンスに基づいた急性膵炎の診療ガイドライン [第1版], 金原出版, 東京, 2003

 

2) 急性膵炎の診療ガイドライン第2版作成委員会編 : エビデンスに基づいた急性膵炎の診療ガイドライン [改訂第2版], 金原出版, 東京, 2007

 

3) 中敏夫, 篠崎正博 : 侵襲後の急性腎不全とその治療. 外科治療 92 : 1007-1013, 2005

Medical*Online

4) 升田好樹, 須佐泰之, 今泉均, 黒田浩光, 他 : 敗血症ショックにおけるhigh mobility group box-1 (HMGB-1) 血中濃度と予後に関する検討. 日本Shock学会雑誌 21 : 43-48, 2006

 

5) Ronco C, Bellomo R, Homei P, Brendolan A, et al : Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure : a prospective randomized trial. Lancet 355 : 26-30, 2000

 

6) 今泉均, 升田好樹, 黒田浩光, 巽博臣. 他 : Septic shockに対する血液浄化のプランニングCRRT vs HVH. エンドトキシン血症救命治療研究会誌 9 : 32-35, 2005

 

7) 小野淳一, 横田貴美夫, 石川純子, 他 : Continuous Renal Replacement TherapyとしてのHigh Volume Continuous Hemodialysisの意義. ICUとCCU 26 : S72-73, 2002

 

8) 西田修, 中村智之, 坪内宏樹, 他 : High-Performance HDF (HP-HDF) の威力 : 全身状態と局所所見の解離 (重症急性膵炎の場合). ICUとCCU 30 : S190-193, 2006

Medical*Online

9) 浦英樹, 浅井康文, 今泉均, 猪股英俊, 他 : 重症急性膵炎に関する血液浄化療法の適応に関する検討. ICUとCCU 25 : s65-67, 2001

 

10) 仲村将高, 平澤博之, 織田成人, 志賀英敏他 : 重症急性膵炎 (SAP) に対する持続的血液濾過透析 (CHDF) の開始基準および離脱基準. ICUとCCU 28 : s150-152, 2004

 

11) 白井邦博, 小倉真治, 吉田省造, 豊田泉, 他 : 当院救命センターにおける重症急性膵炎に対する治療戦略の検討～厚生労働省重症度stage分類別, 松野CT grade分類別に～. 日本外科学会雑誌 108 : 510, 2007

 

12) Imaizumi H, Masuda Y, Ezoe E, et al : Polymyxin B immobilized fiber improves hemodynamic state and mortality in MRSA septic patients. Crit Care Med 28 : Al72, 2000

 

13) 巽博臣, 今泉均, 升田好樹, 杉山由紀, 他 : PMX-DHPによる肺酸素化能の改善に関する検討. エンドトキシン血症救命治療研究会誌 11 : 164-166, 2007

 

P.365 掲載の参考文献

1) 松田兼一, 平澤博之 : 劇症肝炎の現況. ICUとCCU 29 : 83-91, 2005

Medical*Online

2) 坪内博仁, 三代俊治, 持田智, 他 : 劇症肝炎・急性肝不全. 肝臓 48 : 409-428, 2007

 

3) 松田兼一, 平澤博之 : 劇症肝炎と重症急性肝不全. アフェレシスマニュアル, 日本アフェレシス学会編, pp188-195, 秀潤社, 東京, 2004

 

4) 平澤博之, 織田成人, 貞広智仁, 他 : 浄化量を強化した血液浄化法による人工肝補助療法-HFCHDF-. ICUとCCU 31 : 361-369, 2007

Medical*Online

5) Polson J, Lee WM : AASLD position paper : The management of acute liver failure. Hepatology 41 : 1179-1197, 2007

 

6) 与芝真, 井上和明, 山田雅哉 : 劇症肝炎の内科治療システム. 日アフェレシス会誌 22 : 160-166, 2003

 

7) 西田修, 中村智之, 坪内宏樹, 他 : 高効率血液浄化療法 (high flow-volume large size PMMA-HDF : High Performance HDF). 日アフェレシス会誌 26 : 323-331, 2007

 

8) 杉原潤一, 内藤智雄, 石木佳英, 他 : わが国における劇症肝炎の予後予測と肝移植の適応に関する多施設研究 (日本急性肝不全研究会1996年肝移植適応ガイドライン策定の経緯). 肝臓 42 : 543-557, 2001

 

P.370 掲載の参考文献

1) Bernard GN, et al : The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 149 : 818-824, 1994

 

2) 鮎川勝彦 : 急性血液浄化法徹底ガイド 呼吸不全. 救急・集中治療 18 : 119-124, 2006

 

3) The Acute Respiratory Distress Syndrome Network : Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 342 : 1301-1308, 2000

PubMed

4) 日本呼吸療法医学会・多施設共同研究委員会 : ARDSに対するclinical practice guideline 第2版. 人工呼吸 21 : 44-61, 2004

Medical*Online

5) 松田兼一, 平澤博之 : Surviving Sepsis Campaign Guidelineを巡ってRenal Replacement Therapy. ICUとCCU 28 (10) : 859-861, 2004

 

6) Ronco C, Bellomo R, Homel P, et al : Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure : a prospective randomized trial. Lancet 356 : 26-30, 2000

PubMed

7) Ronco C, Bonello M, Bordoni V, et al : Extracorporeal therapies in non-renal disease : Treatment of sepsis and the peak concentration hypothesis. Blood Purif 22 : 164-174, 2004

PubMed

8) Tsusima K, Kubo K, Koizumi T, et al : Direct hemoperfusion using a polymyxin B immobilized column improves acute respiratory distress syndrome. J Clin Apher 17 : 97-102, 2002

 

P.375 掲載の参考文献

1) Smith J, Greaves I : Crush injury and crush syndrome : a review. J Trauma 54 : S226-S230, 2003

PubMed

2) Altintepe L, Guney I, Tonbul Z, Turk S, et al : Early and intensive fluid replacement prevents acute renal failure in the crush cases associated with spontaneous collapse of an apartment in Konya. Ren Fail 29 : 737-741, 2007

PubMed

3) Mehta RL, Kellum JA, Shah SV, Molitoris BA, et al : Acute Kidney Injury Network : report of an initiative to improve outcomes in acute kidney injury. Crit Care 11 : R31, 2007

PubMed

4) Vinsonneau C, Camus C, Combes A, Costa de Beauregard MA, et al : Continuous venovenous haemodiafiltration versus intermittent haemodialysis for acute renal failure in patients with muitiple-organ dysfunction syndrome : a multicentre randomised trial. Lancet 368 : 379-85, 2006

 

P.379 掲載の参考文献

1) Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee : American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference : Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20 : 864-874, 1992

 

2) Bellomo R, Tipping P, Boyce N : Continuous veno-veous hemofiltration with dialysis removes cytokines from the circulation of septic patients. Crit Care Med 21 : 522-526, 1993

 

3) Cole L, Bellomo R, Journois D, et al : High-volume haemofiltration in human septic shock. Intensive Care Med 27 : 978-986, 2001

PubMed

4) Ronco C, Bellomo R, Homel P, et al : Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure : a prospective randomized trial. Lancet 355 : 26-30, 2000

 

5) Nakada T, Hirasawa H, Oda S, et al : Blood purification for hypercytokinemia. Transfus Apher Sci 35 : 253-264, 2006

PubMed

6) Oda S, Hirasawa H, Shiga H, et al : Sequential measurement of IL-6 blood levels in patients with systemic inflammatory response syndrome (SIRS) /sepsis. Cytokine 29 : 169-175, 2005

PubMed

P.383 掲載の参考文献

1) Blake PG : Adequacy of peritoneal dialysis and chronic peritoneal dialysis prescription. Handbook of Dialysis, Daugirdas Jt, Blake PG, Iug TS (eds), pp387-409, Wolters Kluwer, Philadelphia, 2007

 

2) Haq NV, Nolph KD : Past, Present, and Future of Quantified Peritoneal Dialysis. Semin Dial 14 : 263-267, 2001

 

3) Rabindranah KS, Adams J, Ali TZ, Daly C, et al : Automated vs Continuous ambulatory peritoneal dialysis : a systemic review of randomaized controlled trials. Nephrol Dial Transplant 22 : 2991-2998, 2007

 

4) European Best Practice Guidelines for Peritoneal Dialysis. Nephrol Dial Transplant 20 (suppl 9) : ix1-ix37, 2005

 

P.387 掲載の参考文献

1) Cooper BA, Branley P, Bulfone L, et al : The Intiating Dialysis Early and Late (IDEAL) study. Perit Dial Int 24 : 176-181, 2004

 

2) National Kidney Foundation : K/DOQI clinical practice guidelines and clinical practice recommendations for peritoneal dialysis adequacy, 2006 update. Am Kidney Dis 48 (1 suppl 1) : S1-175, 2006

 

3) European Best Practice Gudelines for peritoneal dialysis : Nephrol Dial Transplant 20 (suppl 9) : 3-35, 2005

 

4) Lo WK, Bergman JM, Burkart J, et al : ISPD Guidelines/Recommendation Guideline on targets for solute and fluid removal in adult patients on chronic peritoneal dialysis. Perit Dial Int 26 : 520-522, 2006

 

5) Bargman JM, Thorpe KE, Churchill DN : Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis : a reanalysis of the CANUSA Study. J Am Soc Nephrol 12 : 2158-2162, 2001

PubMed

6) Paniagua R, Amato D, Vonesh E, et al : Effect of increased peritoneal clearances on mortality rates in peritoneal dialysis : ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 13 : 1307-1320, 2002

PubMed

7) Lo WK, Ho YW, Li CS, et al : Effects of Kt/V on survival and clinical outcome in CAPD patients in a randomized prospective study. Kidney Int 64 : 649-656, 2003

 

P.391 掲載の参考文献

1) 原一平, 相引眞幸, 小倉真治, 他 : 重症急性膵炎症例での腹膜灌流治療中の血中及び腹膜灌流液中のIL-8, 顆粒球エラスターゼ, LDH, アミラーゼ変動の検討. 日救急医会誌 7 : 725-30, 1996

 

2) Ranson JHC, Rifkind KM, Turne JW : Prognostic signs and non-operative peritoneal lavage in acute pancreatitis. Surg Gynecol Obstet 143 : 209-19, 1976

 

3) Ranson JHC, Berman RS : Long Peritoneal lavage decreases pancreatic sepsis in acute pancreatitis. Ann Surg 211 : 708-16, 1990

 

4) Lowrie LH : Renal replacement therapies in pediatric multiorgan dysfunction syndrome. Pediatr Nephrol 14 : 6-12, 2000

PubMed

5) Toto KH : The kidney in multiple organ dysfunction syndrome. Multiple organ dysfunction and failure, 2nd ed, Secor VH (ed), Mosby, St. Louis, 1996

 

6) 西野正人, 田中裕, 杉本壽 : 多臓器不全における血液浄化法. ICUとCCU 23 : 189-196, 1999

Medical*Online

P.395 掲載の参考文献

1) 持田智 : 急性肝不全の診断基準・病型分類・重症度. 内科 95 : 1126-1133, 2005

 

2) Sabin S, Merritt JA : Treatment of hepatic coma in cirrhosis by plasmapheresis and plasma infusion (plasma exchange). Ann Intern Med 68 : 1-7, 1968

PubMed

3) Yoshiba M, Inoue N, Sanjo T, et al : Plasmapheresis in acute liver failure. Plasmapheresis, Nose Y, et al (eds), pp399-406, Raven Press, New York, 1983

 

4) Yoshiba M, Sekiyama K, Inoue K, et al : Accurate prediction of fulminant hepatic failure in severe acute viral hepatitis : multicenter study. J Gasutroenterol 37 : 916-921, 2002

PubMed

5) 兼坂茂, 飯塚一秀, 高橋愛樹, 他 : 劇症肝炎に対する人工肝補助療法. 日救急医会誌 7 : 11-20, 1996

 

6) 今泉均, 佐藤守仁, 七戸康夫, 他 : 急性肝不全に対する持続的血漿交換 (CPE) の意義. 集中治療 9 : 735-742, 1997

 

7) Tygstrup N, Larsen FS, Hansen BA : Treatment of acute liver failure by high volume plasmapheresis. Acute Liver Failure, WM, Williams R (eds), pp267-277, Cambridge Univ Press, 1997

 

8) Clemmesen JO, Kondrup L, Nielsen LB, et al : Effects of high-volume plasmapheresis on ammonia, urea, and amino acids in patients with acute liver falure. Am J Gastroenterology 96 : 1217-1223, 2001

 

9) 兼坂茂, 渡辺励, 丸岡直隆, 佐々木純, 他 : 敗血症性肝腎障害患者に対する血液濾過透析の効果. 日本腹部救急医学会雑誌 25 : 697-700, 2005

 

10) Sadahiro T, Hirasawa H, Oda S, et al : Usefulness of plasma exchange plus continuous hemodiafiltration to reduce adverse effects associated with plasma exchange in patients with acute liver failure. Crit Care Med 29 : 1386-1392, 2001

PubMed

11) Demetriou AA, Brown RS, Busuttil RW, et al : Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg 239 : 660-670, 2004

PubMed

12) Khuroo MS, Khuroo MS, Farahat KCL : Molecular adsorbent recirculating system for acute and acute-on chronic liver failure : A mete-analysis. Liver Transpl 10 : 1099-1106, 2004

 

P.398 掲載の参考文献

1) Franchini M, Grandini G, Di Paolnantonio T, Mariani G : Acquired Hemophilia A : A Concise Review. Am J Hematol 80 : 55-63, 2005

 

2) Green D, Lechner K : A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb haemost 46 : 200, 1981

PubMed

3) Sunagawa T, Uezu Y, Kodena K, et al : Successful treatment of a non-hemophilic patients with inhibitor to factor VIII by double filtration plasmapheresis. Br J Haemotol 104 : 465-467, 1999

 

4) Jansen M, Schmaldienst S, Banyai S, et al : Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb). Br J Haematol 112 : 91-97, 2001

PubMed

5) Ogata H, Sakai S, Koiwa F, et al : Plasma exchange for acquired hemophilia : a case report. Ther Apher 3 : 320-322, 1999

PubMed

6) Hay CR, Brown S, Collins PW, et al : The diagnosis and management of factor VIII and IX inhibitors : a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol 133 : 591-605, 2006

PubMed

P.404 掲載の参考文献

1) Lee WC, Chen MF : Assessment of hepatic reserve for indication of hepatic resection : how I do it. J Hepatobiliary Pancreat Surg 12 : 23-26, 2005

 

2) 松下通明, 内野純一 : 肝疾患-術後肝不全. 血液浄化療法, 阿岸鉄三編, pp160-164, 医学書院, 東京, 1996

 

3) 松下通明, 神山俊哉 : I 診断・治療アルゴリズム, 総論 5. 肝機能評価による切除可能な区域と治療. EBM外科標準診療, 藤堂省, 松下通明編, pp9-10, 医学書院, 東京, 2003

 

4) 川村秀樹, 神山俊哉, 倉内宣明, 他 : 99mTc-GSAシンチグラフィを用いた肝障害度別換算ICGRI5による肝予備能の評価. 日消外会誌 37 : 14-20, 2004

 

5) 小玉正智, 谷徹, 井上昇 : "術後肝不全" に対する血漿交換療法の現状. 日外会誌 94 : 704-713, 1993

 

6) 伊神剛, 西尾秀樹, 梛野正人, 他 : 血管浸潤例の術前処置の問題点-門脈塞栓術の適応は?-. 胆と膵 26 : 603-607, 2005

Medical*Online

7) Wilasrusmee C, Siritheptawee S, Kanchanapanjapon S, et al : Ultrastructural changes in cirrhotic and noncirrhotic patients due to hepatectomy. J Hepatobiliary Pancreat Surg 11 : 266-271, 2004

PubMed

8) Tsuruga Y, Kiyono T, Matsushita M, et al : Effect of intrasplenic transplantation of immortalized human hepatocytes in the treatment of acetaminophen-induced acute liver failure SCID Mice. Transplantation Proceedings 40 : 617-619, 2008

PubMed

P.408 掲載の参考文献

1) Lee WM : Acute liver failure. N Engl J Med 329 : 1862-1872, 1993

PubMed

2) Yoshiba M, Inoue K, Sekiyama K, et al : Favorable effect of new artificial liver support on survival of patients with fulminant hepatic failure. Artif Organs 20 : 1169-1172, 1996

PubMed

3) 平澤博之, 織田成人, 貞広智仁, 他 : 浄化量を強化した血液浄化法による人工肝補助療法-HFCHDF-. ICUとCCU 31 (5) : 361-369, 2007

Medical*Online

4) 西田修, 中村智之, 坪内宏樹, 他 : 高効率血液浄化療法 (high flow-volume large size PMMA-HDF : High Performance HDF). 日本アフェレシス学会雑誌 26 (3) : 323-331, 2007

 

5) Martin AP, Bartels M, Hauss J, et al : Overview of the MELD Score and the UNOS Adult Liver Allocation System. Transplant Proc 39 : 3169-3174, 2007

PubMed

6) Boyle M, Kurtovic J, Bihari D, et al : Equipment review : The molecular adsorbents recirculating systems (MARS). Crit Care 8 : 2018-286, 2004

 

7) Rifai K, Manns MP : Review Article : Clinical Experience with Prometheus. Ther Apher Dial 10 (2) : 132-137, 2006

PubMed

8) Rozga J, Umehara Y, Trofimenko A, et al : A Novel Plasma Filtration Therapy for Hepatic Failure : Preclinical Studies Ther Apher Dial 10 (2) : 138-144, 2006

PubMed

9) Li LJ, Liu XL, Xu XW, et al : Comparison of Plasma Exchange With Different Membrane Pore Sizes in the Treatment of Severe Viral Hepatitis. Ther Apher Dial 9 (5) : 396-401, 2005

PubMed

10) 江口豊 : 重症肝障害におけるPlasma Dia-filtration (PDF) -Plasma Filtration with Dialysis-療法. 日本アフェレシス学会雑誌 26 (3) : 310-314, 2007

 

P.412 掲載の参考文献

1) Adams WS, Blahd WH, Bassert SH : A method of human plasmapheresis. Proc Soc Exp Biol Med 80 : 377, 1952

 

2) Kyle RA, Therneau TM, Rajkumar SV, et al : A long term study of prognosis in monoclonal gammopathy undetermined significance. N Engl J Med 346 : 564-569, 2002

PubMed

3) 河野道生, 島崎千尋, 村上博和編, 原田実根監修 : 多発性骨髄腫 Up-to-date, メディカルレビュー社, 東京, 2006

 

4) 上田恭典 : 原発性マクログロブリン血症, 多発性骨髄腫をはじめとするparaprotein血症に対する治療的ヘムアフェレシス. 日本アフェレシス学会雑誌 18 : 223-228, 1999

 

5) Clark WF, Steward KA, Rock GA, et al : Plasma exchange when myeloma presents as acute renal failure : a randomized controlled trial. Ann Intern Med 143 : 777-784, 2005

 

P.416 掲載の参考文献

1) Adams WS, Blahd WH, Bassert SH : A method of human plasmapheresis. Proc Soc Exp Biol Med 80 : 377, 1952

 

2) Berger F, Isaacson PG, Piris MA, et al : Lymphoplasmacytic Lymphoma/Waldenstrom macrogloburinemia. Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues, Jaffe ES, et al (eds), pp132-134, IARC Press, Lyon, 2001

 

3) 上田恭典 : 原発性マクログロブリン血症, 多発性骨髄腫をはじめとするparaprotein血症に対する治療的ヘムアフェレシス. 日本アフェレシス学会雑誌 18 : 223-228, 1999

 

4) Fonseca R, ayman S : Waldenstrom Macroglobulinaemia. Brit J Haematol 138 : 700-720, 2007

 

P.420 掲載の参考文献

1) Chapter 29 Diseases and injuries of the fetus and newborn. WiHiams Obstetrics 22nd edition, Cunningham FG (ed), p665, McGraw-Hill Professional, New York, 2005

 

2) Parer JT : Severe Rh isoimmunization-current methods of in utero diagnosis and treatmenl. Am J Obstet Gynecol 158 : 1323-1329, 1988

PubMed

3) 浮田昌彦, 矢切良穂, 上田恭典 : 母児免疫疾患に対する血漿交換療法 (抗体除去療法). 周産期医学 19 : 59-66, 1989

 

4) 上田恭典 : 血液型不適合妊娠. 新版 アフェレシスマニュアル, 日本アフェレシス学会編, pp337-340, 秀潤社, 東京, 2004

 

5) Taniguchi F, Horie S, Tsukihara S, et al : Successful management of a P-incompatible pregnancy using double filtration plasmapheresis. Gynecol Obstet Invest 56 : 117-120, 2003

 

6) Hanafusa N, Noiri E, Yamashita T, et al : Successful treatment by double filtrate plasmapheresis in a pregnant woman with the rare P blood group and a history of multiple early miscarriages. Ther Apher Dial 10 : 498-503, 2006

 

P.427 掲載の参考文献

1) 藤村吉博 : 血栓性血小板減少性紫斑病の分子機構. 今日の移植 19 : 511-517, 2006

Medical*Online

2) 松本雅則 : TTPの診断と治療の進歩. 日本血栓止血学会誌 17 : 393-401, 2006.

 

3) Yagita M, Uemura M, Nakamura T, Kunitomi A, et al : Development of ADAMTSI3 inhibitor in a patient with hepatitis C virus-related liver cirrhosis causes thrombotic thrombocytopenic purpura. J Hepatol 42 : 420-421, 2005

 

4) Kitano K, Gibo Y, Kamijo A, Furuta K, et al : Thrombotic thrombocytopenic purpura associated with pegylated-interferon alpha-2a by an ADAMTS13 inhibitor in a patient with chronic hepatitis C. Haematologica 91 (8 suppl) : ECR34, 2006

 

5) 金子仁臣, 松本雅則, 岡本浩平, 蝶名林和久, 他 : Ritukimabとvincristineの併用が奏効した難治性血栓性血小板減少性紫斑病. 臨床血液 48 : 144-147, 2007

 

P.431 掲載の参考文献

1) Noris M, Remuzzi G : Hemolytic uremic syndrome. J Am Soc Nephrol 16 : 1035-1050, 2005

PubMed

2) Dragon-Durey MA, Loirat C, Cloarec S, Macher MA, et al : Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 16 : 555-563, 2005

PubMed

3) Ruggenenti P, Noris M, Remuzzi G : Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 60 : 831-846, 2001

PubMed

4) 日高義彦, 黒澤優子, 北原正志, 小池健一, 他 : Factor Hの遺伝子変異と蛋白機能異常が認められた溶血性尿毒症症候群の1例. 日本小児腎臓病学会雑誌 21 (1) (suppl) : 135, 2008

Medical*Online

P.435 掲載の参考文献

1) Weinstein L : Syndrome of hemolysis, elevated liver enzymes, and low platelet count : A severe consequence of hypertension in pregnancy. Am J Obstet Gynecol 15 : 159-167, 1982

 

2) Rath W, et al : HELLP syndrome. J Perinat Med 28 : 249-260, 2000

PubMed

3) Sibai BM, et al : Acute renal failure in pregnancies complicated by hemolysis, elevated liver enzymes, and low platelets. Am J Obstet Gynecol 168 : 1682-1690, 1993

PubMed

4) Sibai BM : The HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet count) : Much ado about nothing? Am J Obstet Gynecol 162 : 311-316, 1990

PubMed

5) van Runnard Heimel PJ, et al : A randomized placebo-controlled trial of prolonged predonisoline administration to patients with HELLP syndrome remote from term. Eur J Obstet Gynecol Reprod Biol 128 : 187-193, 2006

PubMed

6) Fonseca JE, et al : Dexamethasone treatment does not improve the outcome of women with HELLP syndrome : a double-blind, placebo-controlled, randomized clinical trial. Am J Obstet Gynecol 193 : 1591-1598, 2005

PubMed

7) Martin JN, et al : Plasma exchange for preeclampsia : I. Postpartum use for persistently severe preeclampsia-eclampsia with HELLP syndrome. Am J Obstet Gynecol 162 : 126-137, 1990

PubMed

8) Martin JN, et al : Pasma exchange for preeclampsia : III. Immediate peripartal utilization for selected patients with HELLP syndrome. J Clin Apheresis 9 : 162-165, 1994

 

P.440 掲載の参考文献

1) Hoch W, McConville J, Helms S, et al : Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nature Med 7 : 365-368, 2001

 

2) Vincent A : Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol 2 : 797-804, 2002

PubMed

3) Conti-Fine BM, Milani M, Kaminski HJ : Myasthenia gravis : past, present, and future. J Clin Invest 116 : 2843-2854, 2006

PubMed

4) 村井弘之, 山下夏美 : 重症筋無力症の疫学厚生労働省免疫性神経疾患に関する調査研究班臨床疫学調査結果から. 脳 21 (11) : 227-231

 

5) 本村政勝 : 重症筋無力症の病態 抗MuSK抗体を中心に… 新たな抗体の発見. 脳 21 (11) : 232-237

 

P.446 掲載の参考文献

1) Guillain-Barre syndrome study group : Plasmapheresis and acute Guillain-Barre syndrome. Neurology 35 : 1096-1104, 1985

 

2) French cooperative group in plasma exchange in Guillain-Barre syndrome : Efficiency of plasma exchange in Guillain-Barre syndrome : Role of replacement fluids. Ann Neurol 22 : 753-761, 1987

PubMed

3) French cooperative group on plasma exchange in Guillain-Barre syndrome : Appropriate number of plasma exchanges in Guillain-Barre syndrome. Ann Neurol 41 : 298-306, 1997

 

4) Diener HC, Haupt WE Kloss TM, et al : A preliminary, randmized, multicenter study comparing intravenous immunoglobulin, plasma exchange, and immune adsorption in Guillain-Barre syndrome. Eur Neurol 46 : 107-109, 2001

 

5) Haupt WF, Birkmann C, van der Ven C, et al : Apheresis and selective adsorption plus immunoglobulin treatment in Guillain-Barre syndrome. Ther Apher 4 : 198-200, 2000

PubMed

P.449 掲載の参考文献

1) Joint Task Force of the EFNS and the PNS : EFSN/PNS Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy : report of a joint task force of the EFNS and PNS. J Peripher Nerv Syst 10 : 220-228, 2005

 

2) 渋谷統寿, 高昌星, 松尾秀徳後藤公文, 他 : 神経疾患. 新版アフェレシスマニュアル ; 難治疾患の治療革命, 日本アフェレシス学会編, pp297-319, 秀潤社, 東京, 2004

 

3) Dyck PJ, Daube J, OBrien P, Pineda A, et al : Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 314 : 461-465, 1986

PubMed

4) Hahn AF, Bolton CF, Pillay N, Chalk C, et al : Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. A double blind, sham-controlled, crossover study. Brain 119 : 1055-1066, 1996

PubMed

5) Mehndiratta MM, Hughes RAC, Agarwal P : Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database of Systematic Reviews 2004, Issue 3. Art. No. : CD003906. DOI : 10.1002/1465185&CD003906. pub2.

 

P.453 掲載の参考文献

1) Misu T, Fujihara K, Kakita A, et al : Loss of aquaporin 4 in lesions of neuromyelitis optica : distinction from multiple sclerosis. Brain 130 : 1224-1234, 2007

PubMed

2) Keegan M, K6nig F, McClelland R, et al : Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 366 : 579-582, 2005

 

3) Breij E, Brink B, Veerhuis R, et al : Homogeneity of Active Demyelinating Lesions in Established Multiple Sclerosis. Ann Neurol 63 : 16-25, 2008

PubMed

4) Weinshenker B, O'Brien P, Petterson T, et al : A Randomized Trial of Plasma Exchange in Acute Central Nervous System Inflammatory Demyelinating Disease. Ann Neurol 46 : 878-886, 1999

PubMed

5) Watanabe S, Nakashima I, Misu T, et al : Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 13 : 128-132, 2007

PubMed

6) Pittock SJ, Weinshenker BG, Lucchinetti CF, et al : Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 63 : 964-968, 2006

PubMed

P.458 掲載の参考文献

1) Mori M, Kuwabara S, Fukutake T, Hattori T : Plasmapheresis and Miller Fisher syndrome : analysis of 50 consecutive cases. J Neurol Neurosurg Psychiatry 72 : 680, 2002

 

2) Yeh JH, Chen WH, Chen JR, Chiu HC : Miller Fisher syndrome with central involvement : successful treatment with plasmapheresis. Ther Apher 3 : 69-71, 1999

PubMed

3) Nobile-Orazio E, Meucci N, Baldini L, Di Troia A, et al : Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain 123 : 710-717, 2000

PubMed

4) Umehara F, Kore-Eda Y, Arime T, Kubota R, et al : Chronic sensory ataxic neuropathy and ophthalmoplegia with oculomotor nerve hypertrophy associated with IgM antibodies against gangliosides containing disialosyl groups. J Neurol Neurosurg Psychiatry 62 : 673-674, 1997

PubMed

5) Otsuka R, Umehara F, Arimura K, Maruyama Y, et al : Necrotising vasculitis with conduction block in mononeuropathy multiplex with cold agglutinins. J Neurol Neurosurg Psychiatry 67 : 556-557, 1999

PubMed

6) van den Berg JS, van Engelen BG, Boerman RH, de Baets MH : Acquired neuromyotonia : superiority of plasma exchange over high-dose intravenous human immunoglobulin. J Neurol 246 : 623-625, 1999

PubMed

P.462 掲載の参考文献

1) Lewis EJ, et al : A controlled trial of plasmapheresis therapy in severe lupus nephritis. N Engl J Med 326 : 1373-1379, 1992

PubMed

2) Danieli MG, et al : Synchronised therapy and high-dose cyclophosphamide in proliferative lupus nephritis. J Clin Apheresis 17 : 72-77, 2002

PubMed

3) 津田裕士 : 難治性ループス腎炎に対する血漿交換療法とシクロフォスファミドパルス療法の比較検討. 透析会誌 33 : 103-104, 2000

 

4) 山路健 : アフェレシス療法と膠原病. Medical Practice 23 : 649-653, 2006

Medical*Online

5) 梁広石 : 臨床編リウマチ・膠原病 全身性エリテマトーデス. Clinical Engineering (別冊アフェレシスマニュアル難治疾患の治療革命) : 282-286, 2004

 

P.467 掲載の参考文献

1) van der Bijl E, Allaart CF, Breedveld FC, et al : Rheumatoid Vasculitis Treated with Infliximab. J Rheumatol 32 : 1607-1609, 2005

 

2) Unger L. Kayser M, Nusslein HG : Successful treatment of sever rheumatoid vasculitis by infliximab. Ann Rheum Dis 62 : 587-588, 2003

PubMed

3) 鈴木王洋 : 悪性関節リウマチに対する白血球除去療法. 日本アフェレシス学会雑誌 14 (2) : 244-259, 1995

 

4) 津田裕士, 井上昇, 鈴木満, 斎藤明, 他 : 慢性関節リウマチに対するリンパ球除去療法. 日本アフェレシス学会雑誌 20 (1) : 33-37, 2001

 

P.472 掲載の参考文献

1) 急速進行性腎炎症候群の診療指針. 日腎会誌 44 (2) : 55-82, 2002

 

2) 厚生労働省構成化学特定疾患対策研究事業 難治性血管炎に関する調査研究班編 : 難治性血管炎の診療マニュアル, pp50-51, 2002

 

3) 塩沢俊一 : 膠原病学免疫学・リウマチ性疾患の理解のために (改訂第3版), pp390-427, 丸善, 東京, 2008

 

4) 東京女子医科大学附属膠原病リウマチ痛風センター編 : 膠原病・リウマチ診療, 改訂第2版, pp166-169, メジカルビュー社, 東京, 2007

 

5) 東正徳, 佐々木信, 望月吉郎, 中原保治, 他 : 血漿交換にて救命できたANCA関連肺胞出血の一例. 日本呼吸器学会誌 45 : 21-25, 2007

 

6) アフェレシスマニュアル-難治疾患の治療革命 (クリニカルエンジニアリング別冊), 日本アフェレシス学会編, pp391-401, 秀潤社, 東京, 2004

 

7) Sanada S, Ookawara S, Shindo T, Morino K, et al : A case report of the effect of plasma exchange on reactive hemophagocytic syndrome associated with toxic shock syndrome. Ther Apher Dial 8 : 503-506, 2004

 

8) 池上達義, 福原晶子, 渡邊茂樹, 杉田孝, 他 : 胸膜炎・心外膜炎で発症し診断に苦慮したステロイド抵抗性成人発症Still病の1例. 日本呼吸器学会誌 44 : 389-393, 2006

 

9) Lepore L, Agosti E, Pitacco F, Panizon F : Therapy with plasmapheresis and lymphoplasmapheresis combined with immunosuppressive agents in 2 cases of intractable juvenile rheumatoid arthritis. Pediatr Med Chir 9 : 321-324, 1987

PubMed

P.476 掲載の参考文献

1) 小川秀興, 他 : 天疱瘡の血漿交換療法. 順天堂医学 25 : 421-425, 1979 (文献なし)

 

2) 北島康雄 : 厚生労働省稀少難治性皮膚疾患に関する調査研究班 平成17年度研究報告書, pp49-51, 2006

 

3) 最新皮膚科学大系 6. pp2-140,

 

P.483 掲載の参考文献

1) Yamada H, Takamori K, Yaguchi H, Ogawa H : A study of the efficacy of plasmapheresis for the treatment of drug induced toxic epidermal necrolysis. Therapeutic Apheresis 2 : 153-1561998

 

2) Yamada H, Takamori K : Plasmapheresis for the treatment of toxic epidermal necrolysis, in Japan. Therapeutic Apheresis Dialysis 2008 (in press)

 

3) 花田勝美, 高橋正明, 平山順朗 : 二重濾過血漿分離交換法の奏効したtoxic epidermal necrolysis (TEN) の1例. 日皮会誌 98 : 952, 1988

 

4) 出光俊郎, 加倉井真樹 : 症例1 : 眼症状を主体とし, 血漿交換が著効を示したSJS. 薬疹のすべて, 池澤善郎, 相原道子編, pp113-116, 南江堂, 東京, 2008

 

5) 山根裕美子, 相原道子, 池澤善郎 : 最近のSJSとTEN病態と動向. 臨床皮膚科 61 : 42-45, 2007.

 

6) 阿部理一郎 : Fas/FasLシステムと重症薬疹. 日本皮膚アレルギー学会雑誌 13 : 53-57, 2005

Medical*Online

P.488 掲載の参考文献

1) Thompson GR, Lowenthal R, Myant NB : Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet 1 (7918) : 1208-1211, 1975

PubMed

2) Kajinami K, Mabuchi H : Therapeutic effects of LDL apheresis in the prevention of atherosclerosis. Curr Opin Lipid 10 : 401-406, 1999

PubMed

3) Koizumi J, Koizumil. Uno Y, Inazu A, et al : Reduction of lipoprotein (a) by LDL-apheresis using a dextran sulfate cellulose column in patients with familial hypercholesterolemia. Atherosclerosis 100 : 65-74, 1993

PubMed

4) Thompsen J, Thompson PD : A systemic review of LDL apheresis in the treatment of cardiovascular disease. Atherosclerosis 189 : 31-38, 2006

 

5) Matsuzaki M, Hiramori K, Imaizumi T, Kitabatake A, et al : Intravascuiar ultrasound evaluation of coronary plaque regression by low-densitiy lipoprotein apheresis in familial hypercholesterolemia. The Low-Density Lipoprotein Apheresis Coronary Morphology and Reserve Trial (LACMART). J Am Coll Cardiol 40 : 220-227, 2002

 

6) Kanemitsu S, Takekoshi N, Matsui S, Tsugawa H, et al : Short-term and long-term effects of low-density lipoprotein (LDL) apheresis on restenosis after percutaneous transluminal coronary angioplasty (PTCA) : Is lowering Lp (a) by LDL apheresis effective on restenosis after PTCA? Ther Apher 2 : 65-70, 1998

PubMed

7) Tamai O, Matsuoka H, Itabe H, Wada Y, et al : Single LDL apheresis improves endothelium-dependent vasodilation in hypercholesterolemic humans. Circulation 95 : 76-82, 1997

PubMed

8) Koga N, Iwata Y : Pathological and angiographic regression of coronary atherosclerosis by LDL-apheresis in a patient with familial hypercholesterolemia. Atherosclerosis 90 : 9-21, 1991

 

P.494 掲載の参考文献

1) 米川元樹, 川村明夫 : Cryofiltrationにおける最近の技術的動向. 日本アフェレシス学会雑誌 21 : 20-27, 2002

 

2) 米川元樹, 目黒順一, 久木田和丘, 他 : 血液粘稠度からみたCryofiltrationの有用性. Therapeutic plasmapheresis VIII : 201-204, 1989

 

3) Kawamura A, Horie T, Tsuda I, et al : Prevention of limb amputation in patients with limb ulcers by autologous peripheral blood mononuclear cell implantation. Ther Apher Dial 9 : 59-63, 2005

PubMed

4) Kawamura A, Horie T, Tsuda I, et al : Clinical study of therapeutic angiogensis by autologous peripheral blood stem cell transplantation in 92 patients with critically ischemic limbs. J Artif Organs 9 : 226-233, 2006

 

5) 堀江卓, 川村明夫, 津田一郎, 他 : 末梢血幹細胞による血管再生治療. 日本アフェレシス学会雑誌 25 : 172-182, 2006

 

P.501 掲載の参考文献

1) Kramer P, Wigger W, Rieger J, et al : Arteriovenous haemofiltration : anew and simple method for treatment of overhydrated patients resistant to diuretics. Klin Wochenscher 55 : 1121-1122, 1977

 

2) Marenzi GC, Lauri G, Granzi M, et al : Circulatory response to fluid overload removal by extracorporeal ultrafiltration in refractory congestive heart failure. J Am Coll Cardiol 38 : 936-938, 2001

 

3) Constanzo MR, Guglin ME, Saltzberg MT, et al : Ultrafiltration versus intravenous diuetics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 49 : 675-683, 2007

 

4) Levine B, Kalman J, Mayer L, et al : Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323 : 236-241, 1990

PubMed

5) Torre-Amione G, Kapadia S, Benedict C, et al : Proinflammatory cytokine levels in patients with depressed left ventricular dysfunction : a report from the Study of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 27 : 1201-1206, 1996

 

6) Chen D, Assad-Kottner C, Orrego C, et al : Cytokines and acute heart failure. Crit Care Med 36 : S9-S16, 2008

PubMed

7) Mann DL, McMurray JJV, Packer M, et al : Targeted anticytokine therapy in patients with chronic heart failure : results of Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109 : 1594-1602, 2004

PubMed

8) Chung ES, Packer M, Lo KH, et al : Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure : results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) trial. Circulation 107 : 3133-3140, 2003

 

9) Oda S, Hirasawa H, Shiga H, et al : Continuous hemofiltration/hemodiafiltration in critical care. Ther Apher 6 : 193-198, 2002

PubMed

10) 河西秀樹 : 持続的血液浄化法 (CRRT) としてのCHDF, CHF, CHDの選択. 救急・集中治療 17 : 505-511, 2005

 

11) Libetta C, Sepe V, Zucchi M, et al : Intermittent haemofiltration in refractory congestive heart failure : BNP and balance of inflammatory cytokines. Nephrol Dial Transplant 22 : 2013-2019, 2007

PubMed

12) 永田義毅, 臼田和生, 関口芳輝, 他 : 致死性心室性不整脈の遷延により多臓器不全に陥った劇症型心筋炎の1救命例-神経体液性因子回復過程の検討-. 富山中医誌 26 : 54-58, 2003

 

13) Matsui S, Fu MLX : Myocardial inj ury due to G-protein coupled receptor autoimmunity. Jpn Heart J 39 : 261-274, 1998

 

14) Dorffel WV, Felix SB, Wallukat G, et al : Short-term hemodynamic effects of immunoadsorption in dilated cardiomyopathy. Circulation 95 : 1994-1997, 1997

PubMed

15) Muller J, Wallukat G, Dandel M, et al : Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation 101 : 385-391, 2000

PubMed

16) Staudt A, B6hm M, Brges A, et al : Potential role of autoantibodies belonging to the immunoglobulin G-3 subclass in cardiac dysfunction among patients with dilated cardiomyopathy. Circulation 106 : 2448-2453, 2002

 

17) Wallukat G, Muller J : Specific removal of β1-adrenergic autoantibodies from patients with idiopathic dilated cardiomyopathy. N Engl J Med 347 : 1806, 2002

 

P.504 掲載の参考文献

1) Korbet SM : Primary focal segmental glomerulosclerosis. J Am Soc Nephrol 9 : 1333-1340, 1998

PubMed

2) Marszal J, Saleem MA : The bioactivity of plasma factors in focal segmental glomerulosclerosis. Nephron Exp Nephrol 104 : e1-e5, 2006

PubMed

3) Sharma R, et al : Component of normal serum blocks the focal segmental glomerulosclerosis factor activity in vitro. Kidney Int 58 : 1973-1979, 2000

PubMed

4) Tojo K, Sakai S, Miyahara T : Possible therapeutic application of iow density lipoprotein apheresis (LDL-A) in conjunction with double filtration plasmapheresis (DFPP) in drug-resistant nephrotic syndrome due to focal glomerular sclerosis (FGS). Jpn J Nephrol 30 : 1153-1160, 1988

 

5) Muso E, et al : Significantly rapid relief from steroid-resistant nephrotic syndrome by LDL apheresis compared with steroid monotherapy. Nephron 89 : 408-415, 2001

PubMed

6) Hattori M, et al : Treatment with a combination of low-density lipoprotein apheresis and pravastatin of a patient with drug-resistant nephrotic syndrome due to focal segmental glomerulosclerosis. Pediatr Nephrol 7 : 196-198, 1993

PubMed

7) Hattori M, et al : A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children. Am J Kidney Dis 42 : 1121-1130, 2003

 

8) 村田敏晃, 斉藤喬雄 : ネフローゼ症候群に対するアフェレシス治療. 腎と透析 60 : 240-245, 2006

 

P.508 掲載の参考文献

1) Agishi T, Takahashi K, Yagisawa T, Ota K : Immunoadsorption of anti-A or anti-B antibody for successful kidney transplantation between ABO incompatible pairs and its limitation. Japanese Biosynsorb Research Group. ASAIO Trans 37 : M496-498, 1991

 

2) Stegall MD, Gloor J, Winters JL, Moore SB, et al : A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 6 : 346-351, 2006

PubMed

3) Beimler JH, Susal C, Zeier M : Desensitization strategies enabling successful renal transplantation in highly sensitized patients. Clin Transplant 20 (suppl 17) : 7-12, 2006

 

4) Gohh RY, Yango AF, Morrissey PE, Monaco AP, et al : Preemptive plasmapheresis and recurrence of FSGS in high-risk renal transplant recipients. Am J Transplant 5 : 2907-2912, 2005

PubMed

5) Nishi S, Hasegawa S, Gejyo F, et al : A safety measures for double filtration plasma apheresis (DFPP) before ABO-incompatible kidney transplantation. ABO-incompatible Organ Tansplantation from Japan, Takahashi K (ed), pp89-95, Elsevier, Netherlands, 2006

 

6) Saito K, Nakagawa Y, Suwa M, Kumagai N, et al : Pinpoint targeted immunosuppression : anti-CD20/MMF desensitization with anti-CD25 in successful ABO-incompatible kidney transplantation without splenectomy. Xenotransplantation 13 : 111-117, 2006

PubMed

P.512 掲載の参考文献

1) Churg J, Bernstein J, Glassock RJ : Classification of glomerular disease. Renal disease. Classification and atlas of glomerular diseases, 2nd ed, Churg J, Bernstein J, Glassock RJ (eds), Igaku-Shoin, New York, Tokyo, 1995

 

2) 急速進行性糸球体腎炎診療指針作成合同委員会 : 急速進行性腎炎症候群の診療指針. 日腎会誌 44 : 55-82, 2002

 

3) 山縣邦弘, 小山哲夫 : ANCA関連血管炎. 腎と透析 60 : 252-256, 2006

 

4) 山縣邦弘, 平山浩一, 高橋秀人, 小山哲夫 : 我が国の急速進行性糸球体腎炎の治療におけるアフェレシス療法の位置づけ. 日本アフェレシス学会雑誌 25 : 12-20, 2006

 

5) Rifle G, Chalopin JM, Zech P, et al : Treatment of idiopathic acute crescentic glomerulonephritis by immunudepression and plasma-exchanges. A prospective randomised study. Proc EDTA 18 : 493-502, 1980

 

6) Mauri JM, Gonzalez MT, Poveda R, et al : Therapeutic plasma exchange in the treatment of rapidly progressive glomerulonephritis. Plasma Ther Transfus Technol 6 : 587-591, 1985

 

7) Glockner WM, Sieberth HG, Wichmann HE, et al : Plasma exchange and immunosuppression in rapidly progressive glomerulonephritis : a controlled, multicenter study. Clin Nephrol 29 : 1-8, 1988

 

8) Pusey CD, Rees AJ, Evans DJ, et al : Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int 40 : 757-763, 1991

PubMed

9) Cole E, Cattran D, Magil A, et al : A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis. Am J Kidney Dis 20 : 261-269, 1992

PubMed

10) Furuta T, Hotta O, Yusa N, et al : Lymphocytapheresis to treat rapidly progressive glomerulonephritis : a randomised comparison with steroid-pulse treatment. Lancet 352 (9123) : 203-204, 1998

PubMed

11) Zauner I, Bach D, Braun N, et al : Predictive value of initial histology and effect of plasmapheresis on long-term prognosis of rapidly progressive glomerulonephritis. Am J Kidney Dis 39 : 28-35, 2002

PubMed

12) Jayne DR, Gaskin G, Rasmussen N, et al : Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 18 : 2180-2188, 2007

 

13) Hasegawa M, Watanabe A, Takahashi H, et al : Treatment with cytapheresis for antineutrophil cytoplasmic antibody-associated renal vasculitis and its effect on anti-infiammatory factors. Ther Apher Dial 9 : 297-302, 2005

 

14) Simpson IJ, Doak PB, Williams LC, et al : Plasma exchange in Goodpasture's syndrome. Am J Nephrol 2 : 301-311, 1982

PubMed

15) Johnson JP, Moore J Jr, Austin HA 3rd, et al : Therapy of anti-glomerular basement membrane antibody disease : analysis of prognostic significance of clinical, pathologic and treatment factors. Medicine (Baltimore) 64 : 219-227, 1985

PubMed

16) Levy JB, Turner AN, Rees AJ, et al : Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med 134 (11) : 1033-1042, 2001

PubMed

P.516 掲載の参考文献

1) Wallace DJ : Apheresis for Rheumatic and other autoimmune conditions : Where Do We Stand? Therapeuic Apheresis and Dialysis 7 : 143-144, 2003

 

2) Lewis EJ, Hunsicker LG, Lan SP, et al : A controlled trial of plasmaphersis therapy in severe lupus nephritis. N Engl J Med 326 : 1373-1379, 1992

 

3) 若井幸子, 湯村和子 : Lupus腎炎における血漿交換療法の適応基準の検討. 日腎会誌 27 : 703-713, 1990

 

4) 井野純, 武井卓, 板橋美津世, 他 : 当施設におけるSLEに対する免疫吸着療法の検討. 透析会誌 40 (suppl 1) : 594, 2007

 

P.522 掲載の参考文献

1) 冨岡譲二 : 血液浄化法. 日本中毒学会ホームページ http://jsct.umin.jp/page041.html

 

2) 中永士師明 : 重症ベラバミル中毒に対してMolecular Adsorbent Recirculating System (MARSR) 療法を施行した1例. 日職災医誌 52 : 321-326, 2004

 

3) de Pont AC : Extracorporeal treatment of intoxications. Curr Opin Crit Care 13 : 668-73, 2007

PubMed

4) 島田二郎, 田勢長一郎 : 中毒. "急性血液浄化法マニュアル", 篠崎正博, 秋澤忠男編, pp120-131, 南江堂, 東京, 2002

 

5) Pond SM : Diuresis, dialysis, and hemoperfusion : Indication and benefits. Emerg Med Clin North Am 2 : 29-45, 1984

PubMed

P.526 掲載の参考文献

1) Cruz DN, Perazella MA, Bellomo R, et al : Effectiveness of polymyxin B-immobiiized fiber column in sepsis : a systematic review. Crit Care 11 : R47, 2007

PubMed

2) Nakamura T, Suzuki T, Kawagoe Y, Koide H : Polymyxin B-immobilized fiber hemoperfusion attenuates increased plasma atrial natriuretic peptide and brain natriuretic peptide levels in patients with septic shock. ASAIO J 54 : 210, 2008

PubMed

3) Nakamura T, Kawagoe Y, Ueda Y, et al : Polymyxin B-immobilized fiber hemoperfusion reduces urinary 8-hydroxy-2'-deoxyguanosine levels in patients with septic shock. Clin Int Care 17 : 95, 2008

 

4) Yamamoto T, Noiri E, Ono Y, et al : Renal L-type fatty acid-binding Protein in acute ischemic injury. J Am Soc Nephrol 18 : 2894, 2007

PubMed

5) Nakamura T, Sugaya T, Koide H : Urinary liver-type fatty acid-binding protein in septic shock-Effect of polymyxin B-immobilized fiber hemoperfusion. Shock (in press)

 

6) Nakakura T, Kawagoe Y, Suzuki T, et al : Polymyxin B-immobilized fiber hemoperfusion with the PMX-05R column in elderly patients suffering from septic shock. Am J Med Sci 334 : 244, 2007

 

P.530 掲載の参考文献

1) Sawada K, Ohnishi K, Fukui S, Yamada K, et al : Leukocytapheresis therapy, performed with leukocyte removal filter for inflammatory bowei disease. J Gastroenterol 30 : 322-329, 1995

 

2) Shimoyama T, Sawada K, Hiwatashi N : Safety and efficacy of granulocytes and monocyte adsorption apheresis in patients with active ulcerative colitis : a multicenter study. J Clin Apher 16 : 1-9, 2001

PubMed

3) Sawada K, Muto T, Shimoyama T, Satomi M, et al : Multicenter randomized controlled trial for the treatment of ulcerative colitis with a Leukocytapheresis column. Curr Pharmaceutical Design 9 : 307-321, 2003

 

4) 福永健, 福田能啓, 松本響之 : 難治性潰瘍性大腸炎 患者に対する白血球除去療法 (特にLCAPとGCAP) の効果は? 臨床に直結する消化管疾患治療のエビデンス, 上村直実, 菅野健太郎編, pp234-236, 文光堂, 東京, 2005

 

5) Fukunaga K, Fukuda Y, Sawada K, et al : Poorly controlled ulcerative colitis treated by colectomy during remission induced by extracorporeal leukocyte removal therapy. J Gastroentrol 38 : 684-689, 2003

 

P.535 掲載の参考文献

1) Hidaka T, Suzuki K, Matsuki Y, et al : Filtration leukocytapheresis therapy in rheumatoid arthritis : a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 42 : 431-437, 1999

PubMed

2) Ueki Y, Yamasaki S, Kanamoto Y, et al : Evaluation of filtration leukocytapheresis for use in the treatment of patients with rheumatoid arthritis. Rheumatology 39 : 165-171, 2000

PubMed

3) Ueki Y, Sagawa K, Tanimura A, et al : A multicenter study of leukocytapheresis in rheumatoid arthritis. Clin Exp Rheumatol 25 : 810-816, 2007

 

4) Izumi Y, Tominaga M, Iwanaga N, et al : Twenty-four-week follow-up examination of a leukocytapheresis therapy in rheumatoid arthritis. Mod Rheumatol 16 : 20-23, 2006

PubMed

5) Eguchi K, Saito K, Kondo M, et al : Enhanced effect of high-dose leukocytapheresis using a large filter in rheumatoid arthritis. Mod Rheumatol 17 : 481-485, 2007

PubMed

P.540 掲載の参考文献

1) Falk RJ, Terrell RS, Charles LA, Jennette JC : Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 87 : 4115-4119, 1990

PubMed

2) Eddy AA, Symons JM : Nephrotic cyndrome in childhood. Lancet 362 : 629-639, 2003

 

3) 堺秀人, 黒川清, 小山哲夫. 有村義宏. 他 : 急速進行性糸球体腎炎の診療指針 (解説). 日腎会誌 44 : 55-82, 2002

 

4) Hasegawa M, Watanabe A, Takahashi H, et al : Treatment with cytapheresis for anti-neutrophil cytoplasmic antibody-associated renal vasculitis and its effect on anti-inflammatory factors. Ther Apher Dial 9 : 297-302, 2005

PubMed

5) Hasegawa M, Nishii C, Kabutan N, et al : Effects of cytapheresis on tumor necrosis factor receptor and on expression of CD63 in myeloperoxidase-antineutrophil cytoplasmic autoantibody associated vasculitis. Ther Apher Dial 11 : 337-340, 2007

PubMed

6) Yokoyama H, Shimizu M, Wada T, et al : The beneficial effects of lymphocytapheresis for treatment of nephritic syndrome. Ther Apher Dial 6 : 167-173, 2002

 

病態による血液浄化法・管理の工夫

P.545 掲載の参考文献

1) 日本透析医学会統計調査委員会 : 図説わが国の慢性透析療法の現状 (2005年12月31日現在). 日本透析医学会, 2006

 

2) 日本糖尿病学会編 : 科学的根拠に基づく糖尿病診療ガイドライン, pp 13-19, 南江堂, 東京, 2004

 

3) 日本動脈硬化学会編 : 動脈硬化性疾患予防ガイドライン 2007版

 

4) 日本腎臓学会編 : CKD診療ガイド. 東京医学社, 東京, 2007

 

5) 日本透析医学会 : 透析患者における二次性副甲状腺機能亢進症治療ガイドライン. 透析会誌 39 : 1436-1455, 2006

 

P.550 掲載の参考文献

1) 伊藤克己監修, 服部元史, 金子岩和編 : 小児急性血液浄化療法マニュアル, 医学図書出版, 2002

 

2) 秋岡祐子, 服部元史 : 小児における末期腎不全の治療 (2) 血液透析療法. 臨牀透析 21 : 1359-1365, 2005

 

3) 永渕弘之 : 10kg以下の小児に対する急性血液浄化療法. 日本アフェレシス学会雑誌 26 : 339-345, 2007

 

4) Leteurtre S, Marinot A, Duhamel A, et al : Validation of the paediatric logistic organ dysfunction (PELOD) score : prospective, observational, multicentre study. Lancet 362 : 192-197, 2003

 

5) Richardson DK, Phibbs CS, Gray JE, et al : Birth weight and illness severity : independent predictors of neonatal mortality. Pediatrics 91 : 617-623, 1993

 

P.554 掲載の参考文献

1) Oreopoulos DG : The aging kidney. Adv Perit Dial (suppl ; Peritoneal Dialysis in the Geriatric Patient) 6 : 2-5, 1990

 

2) 日本透析医学会統計調査委員会編 : わが国の慢性透析療法の現況 (2006年12月31日現在)

 

3) 日本透析医学会統計調査委員会編 : わが国の慢性透析療法の現況 (2000年12月31日現在)

 

4) 古賀祥嗣, 平松信, 中山昌明, 他 : 高齢者腹膜透析患者の予後と影響因子に関する多施設共同前向き研究-高齢者腹膜透析研究会 (ゼニーレPD研究会) 中間報告-. 透析会誌 40 (2) : 161-167, 2007

 

5) Hiramatsu M : lmproving outcome in geriatric peritoneal dialysis patients. Perit Dial Int 23 : S34-S89, 2003

 

6) 平松信 : 高齢者のCAPD. 腎と透析 52 : 739-745, 2002

 

7) 平松信, 中村明彦, 長宅芳男 : CAPD管理の実際-CAPDのメリットをどう活かすか-. Medical Practice 19 : 487-490, 2002

 

8) 平松信 : 高齢者PDはなぜよいのか. 腎と透析 57 別冊腹膜透析 2004 : 31-34, 2004

 

P.558 掲載の参考文献

1) 日本透析医学会統計調査委員会 : わが国の慢性透析療法の現況2006年12月31日現在, pp17-20, 日本透析医学会, 東京, 2007

 

2) 柴垣有吾 : 腎不全患者の周術期管理の注意点. 保存期腎不全の診かた 慢性腎臓病 (CKD) のマネジメント, pp169-175, 中外医学社, 東京, 2006

 

3) 速水弘 : 維持透析患者の麻酔. 維持透析患者の周術期管理, 大平整爾監修, pp36-41, 鳥居薬品株式会社, 東京, 2007

 

P.562 掲載の参考文献

1) Gejyo F, Odani S, Yamada T, Honma N, et al : Beta 2-microglobulin : a new form of amyloid protein associated with chronic hemodialysis. Kidney Int 30 : 385-390, 1986

PubMed

2) 下条文武, 山本卓, 風間順一郎, 西慎一, 他 : 長期透析患者における透析アミロイドーシスの臨床病態 (分担研究報告書番号 26). 厚生労働科学研究費補助金 (難治性疾患克服研究事業) アミロイドーシスに関する調査研究班報告書, pp98-100, 2007

 

3) Gejyo F, Homma N, Suzuki Y, Arakawa M : Serum levels of beta 2-microglobulin as a new form of amyloid protein in patients undergoing long-term hemodialysis. N Engl J Med 314 : 585-586, 1986

PubMed

4) Yamamoto S, Yamaguchi I, Hasegawa K, Tsutsumi S, et al : Glycosaminoglycans enhance the trifluoroethanol-induced extension of beta 2-microglobulin-related amyloid fibrils at a neutral pH. J Am Soc Nephrol 15 : 126-133, 2004

 

5) Ohhashi Y, Hasegawa K, Naiki H, Goto Y : Optimum amyloid fibril formation of a peptide fragment suggests the amyloidogenic preference of beta 2-microglobulin under physiological conditions. J Biol Chem 279 : 10814-10821, 2004

PubMed

6) Relini A, De Stefano S, Torrassa S, Cavalleri O, et al : Heparin strongly enhances the formation of beta 2-microglobulin amyloid fibrils in the presence of type I collagen. J Biol Chem 283 : 4912-4920, 2008

PubMed

7) Omori K, Kazama JJ, Song J, Goto S, et al : Association of the MCP-1 gene polymorphism A-2518G with carpal-tunnel syndrome in hemodialysis patients. Amyloid 9 : 175-182, 2002

PubMed

8) Gejyo F, Narita I : Current clinical and pathogenetic understanding of beta 2-m amyloidosis in long-term haemodialysis patients. Nephrology (Carlton, Vic 8 suppl) : S45-49, 2003

 

9) Kazama JJ, Yamamoto S, Takahashi N, Ito Y, et al : Abeta-2M-amyloidosis and related bone diseases. Journal of bone and mineral metabolism 24 : 182-184, 2006

PubMed

10) Jadoul M, Garbar C, Vanholder R, Sennesael J, et al : Prevalence of histological beta 2-microglobulin amyloidosis in CAPD patients compared with hemodialysis patients. Kidney Int 54 : 956-959, 1998

PubMed

11) Narita I, Alchi B, Omori K, Sato F, et al : Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients. Kidney Int 69 : 1626-1632, 2006

PubMed

12) Koda Y, Nishi S, Miyazaki S, Haginoshita S, et al : Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 52 : 1096-1101, 1997

PubMed

13) Mann H, Al-Bashir A, Melzer H, Stiller S : Diacap alpha-polysulfone HI PS : anew dialysis membrane with optimum beta 2-microglobulin elimination. Int J Artif Organs 26 : 461-466, 2003

 

14) Furuya R, Kumagai H, Takahashi M, Sano K, et al : Ultrapure dialysate reduces plasma levels of beta 2-microglobulin and pentosidine in hemodialysis patients. Blood purification 23 : 311-316, 2005

PubMed

15) Nakai S, Iseki K, Tabei K, Kubo K et al : Outcomes of hemodiafiltration based on Japanese dialysis patient registry. Am J Kidney Dis 38 : S212-216, 2001

PubMed

16) 下条文武, 川口良人, 原茂子, 中澤了一, 他 : 透析アミロイドーシスに対する直接血液灌流型β2-ミクログロブリン吸着器「リクセル(R)」の臨床効果 : 前向き多施設コントロールβ2-ミクログロブリン吸着器スタディ (βMACS). 腎と透析 46 : 547-560, 1999

 

17) Abe T, Uchita K, Orita H, Kamimura M, et al : Effect of beta (2) -microglobulin adsorption column on dialysis-related amyloidosis. Kidney Int 64 : 1522-1528, 2003

PubMed

P.566 掲載の参考文献

1) 椿原美治 : 維持血液透析療法 合併症とその対策 循環器合併症 血圧異常 低血圧. 日本臨牀 62 : 225-236, 2004

 

2) 加藤満利子 : 透析低血圧の病態に関する研究. 日腎会誌 29 : 1249-1259, 1987

 

3) 中里聡, 城間陽子, 久保和雄 : 透析低血圧の発症機序と対策. 臨牀透析 13 : 63-69. 1997

 

4) 田部井薫 : 透析低血圧患者の血液浄化法の実際. 臨牀透析 13 : 71-79, 1997

 

5) Iwanaga K, Takamura N, Abe Y, et al : Plasma concentarions of Adrenomedulin and hrelin in hemodialysis patients with sustained and epitopec hypotension. Endcr J 52 : 23-28, 2005

 

6) Kusaba T, Tanda S, Kameyama H, et al : Efficacy of biventricular pacing for dialysis-related hypotension due to idiopathic dilated cardiomyopathy. Clin Exp Nephrol 9 : 255-259, 2005

PubMed

7) 渡邊有三 : 透析療法の合併症 低血圧. 腎と透析 61 (臨時増刊号) : 525-529, 2006

 

8) 佐藤隆, 宮原隆明, 庭山淳, 黒澤武 : 透析困難症に対するAcetate-Free-Biofiltration (AFBF) の有効性の検討. 腎と透析 61 別冊HDF療法 '06 : 201-206, 2006

 

P.572 掲載の参考文献

1) Lafrance JP, Nolin L, Senecal L, Leblanc M : Predictors and outcome of cardiopulmonary resuscitation (CPR) calls in a large haemodialysis unit over a seven-year period. Nephrol Dial Transplant 21 : 1006-1012, 2006

 

2) Soman SS, Sandberg KR, Borzak S, Hudson MP, et al : The independent association of renal dysfunction and arrhythmias in critically ill patients. Chest 122 : 669-677, 2002

PubMed

3) Lin CY, Lin LY, Chen PC : Analysis of T-wave morphology from the 12-lead electrocardiogram for prediction of long-term prognosis in patients initiating haemodialysis. Nephrol Dial Transplant 22 : 2645-2652, 2007

PubMed

4) McIntyre CW, Burton JO, Selby NM, Leccisotti L, et al : Hemodialysis-induced cardiac dysfunction is associated with an acute reduction in global and segmental myocardial blood flow. Clin J Am Soc Nephrol 3 : 19-26, 2008

 

5) Genovesi S, Vincenti A, Rossi E, Pogliani D, et al : Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients. Am J Kidney Dis 51 : 255-262, 2008

 

P.576 掲載の参考文献

1) Ganesh SK, Hulbert-Shearon T, Port FK, Eagle K, et al : Mortality differences by dialysis modality among incident ESRD patients with and without coronary artery disease. J Am Soc Nephrol 14 : 415-424, 2003

PubMed

2) Tonbul Z, Altintepe L, Sozlu C, Yeksan M, et al : Ambulatory blood pressure monitoring in haemodialysis and continuous ambulatory peritoneal dialysis (CAPD) patients. Journal of human hypertension 16 : 585-589, 2002

PubMed

3) Fusshoeller A, Plail M, Grabensee B, Plum J : Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD : a prospective, randomized study. Nephrol Dial Transplant 19 : 2101-2106, 2004

 

4) Pecoits-Filho R, Heimburger O, Barany P, et al : Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 41 : 1212-1218, 2003

PubMed

5) K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 45 : S1-153, 2005

PubMed

6) McIntyre CW, Burton JO, Selby NM, et al : Hemodialysis-induced cardiac dysfunction is associated with an acute reduction in global and segmental myocardial blood flow. Clin J Am Soc Nephrol 3 : 19-26, 2008

 

7) Panichi V, Rizza GM, Paoletti S, et al : Chronic inflammation and mortality in haemodialysis : effect of different renal replacement therapies. Results from the RISCAVID study. Nephrol Dial Transplant 23 : 2337-2343, 2008

PubMed

8) Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, Greenland S, et al : Reverse epidemiology of hypertension and cardiovascular death in the hemodialysis population : the 58th annual fall conference and scientific sessions. Hypertension 45 : 811-817, 2005

PubMed

9) Selby NM, Burton JO, Chesterton LJ, McIntyre CW : Dialysis-induced regional left ventricular dysfunction is ameliorated by cooling the dialysate. Clin J Am Soc Nephrol 1 : 1216-1225, 2006

PubMed

P.583 掲載の参考文献

1) 日本透析医学会統計調査委員会 : わが国の慢性透析療法の現況. 2006年12月31日現在, 2007

 

2) K/DOQI Workgroup K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 45 : S1-153, 2005

PubMed

3) 篠原幸人, 吉本高志, 福内靖男, 他編 : 脳卒中治療ガイドライン 2004, pp104-105, 協和企画, 東京, 2004

 

4) Hirakata H, Yao H, Osato S, et al : CBF and oxygen metabolism in hemodialysis patients : effects of anemia correction with recombinant EPO. Am J physiol 262 : F737-F743, 1992

PubMed

5) Metry G, Wikstrom B, Valind S, et al : Effect of normalization of hematocrit on brain circulation and metabolism in hemodialysis patients. J Am Soc Nephrol 10 : 854-863, 1999

PubMed

6) Holzer H, Manguc K, Pogglitsch H, et al : The effect of hemodialysis on cerebral blood flow. Proc EDTA 18 : 126-132, 1981

 

7) Hirakata H, Kanai H, Nakane H, et al : Depressed cerebral oxygen metabolism in patients with chronic renal failure : apositron emission tomography study. J Jap Socie Dial Ther 34 : 1149-1155, 2001

 

8) Yoshimitsu T, Hirakata H, Fujii K, et al : Cerebral ischemia as a causative mechanism for rapid progression of brain atrophy in chronic hemodialysis patients. Clin Nephrol 53 : 445-451, 2000

PubMed

9) Mizumasa T, Hirakata H, Yoshimitsu T, et al : Dialysis-related hypotension as a cause of progressive frontal lobe atrophy in chronic hemodialysis patients : a 3-year prospective study. Nephron Clin Pract. 97 : c23-c30, 2004

PubMed

10) 平方秀樹, 井関邦敏, 井林雪郎, 他 : 透析患者の脳血管障害に関する研究. 平成8年度厚生科学研究費補助金, 長期慢性疾患総合研究事業 (慢性腎不全) 研究報告集, pp49-54, 1997

 

11) Iseki K, Fukiyama K, The Okinawa Dialysis Study (OKIDS) Group : Clinical demographics and long-term prognosis after stroke in patients on chronic haemodialysis. Nephrol Dial Transplant 15 : 1808-1813, 2000

PubMed

12) 藤島正敏 : 日本人の脳血管障害. 日内会誌 55 : 39-50, 1996

 

13) Toyoda K, Fujii K, Fujimi S, et al : Stroke in patients on maintenance hemodialysis : a 22-year single-center study. Am J Kidney Dis 45 : 1058-1066, 2005

PubMed

14) Dernbach PD, Little JR, Jones SC, et al : Altered Cerebral Autoregulation and CO2 reactivity after aneurismal subarachnoid hemorrhage. Neurosurg 22 : 822-826, 1988

 

15) Walters RJ, Fox NC, Crum WR, Taube D, et al : Heamodialysis and cerebral oedema. Nephron 87 : 143-147. 2001

 

16) Krane NK : Intracranial pressure measurement in a patient undergoing hemodialysis and peritoneal dialysis. Am J Kidney Dis 13 : 336-339, 1989

 

17) Yoshida S, Tajika T. Yamasaki N, et al : Dialysis dysequilibrium syndrome in neurosurgical patients. Neurosurgery 20 : 716-721, 1987

PubMed

18) Adams HP Jr, Adams RJ, Brott T, et al : Guidelines for the early management of patients with ischemic stroke : A scientific statement from the Stroke Council of the American Stroke Association. Stroke 34 : 1056-1083, 2003

PubMed

19) Broderick JP, et al : Guidelines for the management of spontaneous intracerebral hemorrhage : A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 30 : 905-915, 1999

PubMed

P.588 掲載の参考文献

1) O'Hare AM, Vittinghoff E, Hsia J, et al : Renal insufficiency and the risk of lower extremity peripheral arterial disease : Results from the Heart and Estrogen/Progestin Replacement Study (HERS). J Am Soc Nephrol 15 : 1046-1051, 2004

 

2) Koch M, Trapp R, Kulas W, et al : Critical limb ischemia as a main cause of death in patients with end-stage renal disease : a single-centre study. Nephrol Dial Transplant 19 : 2547-2552, 2004

 

3) Okamoto K, Oka M, Maesato K, Ikee R, et al : Peripheral arterial occlusive disease is more prevalent in patients with hemodialysis : Comparison with the findings of multidetector-row computed tomography. Am J Kidney Dis 48 : 269-276, 2006

PubMed

4) 岡本好司, 岡真知子, 真栄里恭子, 真野勉, 他 : 透析患者における下肢閉塞性動脈硬化症～無侵襲診断法について. 脈管学 46 (6) : 829-835, 2006

 

5) O'Hare A : Lower-Extremity Peripheral Arterial Disease among Patients with End-Stage Renal Disease. J Am Soc Nephrol 12 : 2838-2847, 2001

PubMed

6) Dormandy JA, Rutherford RB : TransAtlantic Inter-Consensus (TASC) ; Management of peripheral arterial disease (PAD). J Vasc Surg 31 (suppl 1) : S1-S278, 2000

 

7) Bernstein EF, Fronek A : Current status of noninvasive tests in the diagnosis of peripheral arterial disease. Surg Clin North Am 62 : 473-487, 1982

PubMed

8) Castronuovo JJ Jr, Adera HM, Smiell JM, Price RM : Skin perfusion pressure measurement is valuable in the diagnosis of critical limb ischemia. J Vasc Surg 26 : 629-637, 1997

PubMed

9) Ono K, Tsuchida A, Kawai H, et al : Ankle-brachial blood pressure index predicts all-cause and cardiovascular mortality in hemodialysis patients. J Am Soc Nephrol 14 : 1591-1598, 2003

PubMed

10) Kobayashi S : Applications of LDL-apheresis in nephrology. Clin Exp Nephrol 12 : 9-15, 2008

PubMed

P.593 掲載の参考文献

1) Moe S, Drueke T, Cunningham J, Goodman W, et al : Kidney Disease : Improving Global Outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy : a position statement from Kidney Disease : Improving Global Outcomes (KDIGO). Kidney Int 69 : 1945-1953, 2006

PubMed

2) Massry S : K/DOQI Clinical Practice Guidelines. Am J Kidney Dis 42 (suppl 3) : S1-201, 2003

 

3) 日本透析医学会 : 透析患者における二次性副甲状腺機能亢進症治療ガイドライン. 透析会誌 39 : 1435-1455, 2006

 

4) Rodriguez-Benot A, Martin-Malo A, Alvarez-Lara MA, Rodriguez M, et al : Mild hyperphosphatemia and mortality in hemodialysis patients. Am J Kidney Dis 46 : 68-77, 2005

PubMed

5) Kimata N, Akiba T, Pisoni RL, Albert JM, et al : Mineral metabolism and haemoglobin concentration among haemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 20 : 927-935, 2005

PubMed

6) Noordzij M, Korevaar JC, Boeschoten EW, Dekker FW, et al ; Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD) Study Group : The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD : association with mortality in dialysis patients. Am J Kidney Dis 46 : 925-932, 2005

 

7) Slatopolsky E, Finch J, Brown A : New vitamin D analogs. Kidney Int 85 (suppl) : S83-S87, 2003

PubMed

8) Guerin AP, London GM, Marchais SJ, Metivier F : Arteriai stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 15 : 1014-1021, 2000

 

9) Goodman WG, Goldin J, Kuizon BD, Yoon C, et al : Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342 : 1478-1483, 2000

PubMed

10) Chertow GM, Burke SK, Raggi P ; Treat to Goal Working Group : Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62 : 245-252, 2002

 

11) Okuno S, Ishimura E, Kitatani K, Fujino Y, et al : Presence of abdominal aortic calcification is significantly associated with all-cause and cardiovascular mortality in maintenance hemodialysis patients. Am J Kidney Dis 49 (3) : 417-425, 2007

PubMed

12) Block GA, Raggi P, Bellasi A, Kooienga L, et al : Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 71 (5) : 438-441, 2007

PubMed

13) St Peter WL, Liu J, Weinhandl E, Fan Q : A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis : asecondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis 51 (3) : 362-365, 2008

 

14) Koiwa F, Onoda N, Kato H, Tokumoto A, et al ; ROD 21 Clinical Research Group : Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan. Ther Apher Dial 9 : 340-346, 2005

PubMed

15) Quarles LD, Lobaugh B, Murphy G : Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 75 : 145-150, 1992

PubMed

16) Coen G, Ballanti P, Bonucci E, Calabria S, et al : Renal osteodystrophy in predialysis and hemodialysis patients : comparison of histologic patterns and diagnostic predictivity of intact PTH. Nephron 91 : 103-111, 2002

PubMed

17) Wolisi GO, Moe SM : The role of vitamin D in vascular calcification in chronic kidney disease. Semin Dial 18 : 307-314, 2005

PubMed

18) Arenas MD, Alvarez-Ude F, Gil MT, Soriano A, et al : Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease : changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units. Nephrol Dial Transplant 21 : 1663-1668, 2006

PubMed

19) Moe SM, Chertow GM, Coburn JW, Quarles LD, et al : Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 67 (2) : 760-771, 2005

PubMed

20) Fukagawa M, Yumita S, Akizawa T, Uchida E, et al ; KRN1493 study group : Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant 23 (1) : 328-335, 2008

 

21) Messa P, Macario F, Yaqoob M, Bouman K, et al : The OPTIMA study : assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 3 (1) : 36-45, 2008

PubMed

P.599 掲載の参考文献

1) 天野泉 : 慢性血液透析用バスキュラーアクセスの日本における現況と課題. 臨牀透析 21 (12) : 1577-1582, 2005

 

2) 大平整爾, 内藤秀宗, 天野泉, 他 : 慢性血液透析用バスキュラーアクセスの作製および修復に関するガイドライン. 透析会誌 38 (9) : 1491-1551, 2005

 

3) 秋葉隆 : わが国の慢性透析療法の現況 (2001年12月31日現在). 日本透析医学会, pp426-427, 2002

 

4) Altman SD : Percutaneous angioplasty of resistant, high-grade stenosis using the new ultra-high-pressure conquest balloon. Dial Transplant 33 (1) : 48-50, 2004

 

5) 天野泉, 太田和夫, 酒井真治, 他 : ポリウレタン製人工血管 (Thoratec Vascular Access Graft) の特徴とその臨床使用報告. 腎と透析 41 : 263-268, 1996

 

6) 天野泉 : blood access-最近の話題. 透析療法new wave, 丸茂文昭, 秋葉隆編, pp8-13. 中外医学社, 東京, 1999

 

P.604 掲載の参考文献

1) 深澤瑞也, 松下和通, 神家満学, 望月勉, 他 : 新規挿入術時に行う腹膜透析カテーテルの腹壁固定術 (New PWAT) -PDカテーテル位置異常予防法-. 透析会誌 39 : 235-242, 2006

 

2) 深澤瑞也, 松下和通, 寺本咲子, 宮本達也, 他 : 腹腔鏡下に腹膜透析カテーテル腹壁固定術を施行した2例. 透析会誌 36 : 1567-1572, 2003

 

3) Mujasia S, Cractree JH, Piraino B, et al : PDカテーテルおよび関連合併症の管理, Baxter, 東京, 2006

 

血液浄化のセーフティマネージメント

P.611 掲載の参考文献

1) Peterson HD : Acute encephalopathy occuring during hemodialysis. Arch Intern Med 113 : 877-880, 1964

 

2) Silver SM, et al : Dialysis dysequilibrium syndrome (DDS) in the rat : Role of the 'reverse urea effect'. Kidney Int 42 : 161-166, 1992

 

3) Arieff AI, et al : Brain water and electrolyte metabolism in uremia : Effects of slow and rapid hemodialysis. Kidney Int 4 : 177-187, 1973

PubMed

4) Arieff AI, et al : Central nervous system pH in uremia and the effects of hemodialysis. J Clin Invest 58 : 306-311, 1976

PubMed

5) La Greca G, et al : Studies on brain density in hemodialysis and peritoneal dialysis. Nephron 31 : 146-150, 1982

PubMed

6) Galons JP, et al : Hemodialysis increases apparent diffusion coeffcient of brain water in nephrectomized rats measured by isotropic diffusion-weighted magnetic resonance imaging. J Clin Invest 98 : 750-755, 1996

 

7) Bertrand YM, et al : Intracranial pressure changes in patients with head trauma during haemodialysis. Intensive Care Med 9 : 321-323, 1983

PubMed

8) Krane NK : Intracranial pressure measurement in a patient undergoing hemodialysis and peritoneal dialysis. Am J Kidney Dis 13 : 336-339, 1989

 

9) Davenport A, Bramley PN : Cerebral function analyzing monitor and visual evoked potentiais as a noninvasive method of detecting cerebral dysfunction in patients with acute hepatic and renal failure treated with intermittent machine hemofiltration. Renal Failure 15 : 515-522, 1993

 

10) 金井英俊, 他 : 血液透析後の起立性低血圧に伴う脳血流低下と昇圧薬の効果. 体位変換時の脳血流変動. 経頭蓋超音波ドプラ法による検討. 腎臓 27 : 110-114, 2004

 

11) Ishida I, et al : Hemodiaiysis causes severe orthostatic reduction in blood flow velocity in diabetic hemodialysis patients. Am J Kidney Dis 34 : 1096-1104, 1999

PubMed

12) Barth RH : Pros and cons of short, high efficiency, and high flux dialysis. Replacement of Renal Function by Dialysis, 4th revised ed, Jacobs C, et al (eds), pp418-453, Kuwar Academic Publishers, Boston, 1995

 

P.615 掲載の参考文献

1) 山本壱弥, 松本卓也, 増田卓, 他 : 維持血液透析時に認められる過剰な血圧低下の出現機序に関する検討. 透析会誌 40 : 897-906 : 2007

 

2) Lang SM, Beccker A, Fische R, et al : Acute effects of hemodialysis on lung function in patients with end stage renal disease, Wien Klin Wochenschr 118 : 108-113, 2006

 

3) David JP : Respiratory consideration in patient with renal failure. Respir Care 51 : 413-422, 2006

 

4) Karacan, et al : Pulmonary function in renal transplant recipients and end stage renal disease patients undergoing maintenance dialysis. Transproceed 38 : 396-400, 2006

 

5) 中井滋, 他 : わが国の慢性透析療法の現況. 透析会誌 41 : 1-28 : 2008

 

P.620 掲載の参考文献

1) Lieberman P, et al : The diagnosis and management of anaphylaxis. An updated practice parameter. J Allergy Clin Immunol 115 : S483-523, 2005

 

2) D. G. Ebo, et al : Haemodialysi-associated anaphylactic and anaphylactoid reaction. Allergy 61 : 211-220, 2006

 

3) Simons FE, et al : Epinephrine absorption in children with a history of anaphylaxis. J Allergy Clin Immunol 108 : 871-873, 2001

 

4) Barnard JH : Nonfatal results in third-degree anaphylaxis from hymenoptera stings. J Allergy 45 : 92-96, 1970

PubMed

5) Lee JM, et al : Biphasic anaphylactic reactions in pediatrics. Pediatrics 106 : 762-766, 2000

 

6) Sampson H : Anaphylaxis and Emergency Treatment. Pediatrics 111 : 1601-1608, 2003

PubMed

7) Simons FE : Advances in H1-Antihistamine. N Engl J Med 351 : 2203-2217, 2004

PubMed

8) Kaplan AP : Chronic and angioedema. N Engl J Med 346 : 175-179, 2002

PubMed

9) 岡田正人 : レジデントのためのアレルギー疾患診療マニュアル, 医学書院, 東京, 2006

 

P.625 掲載の参考文献

1) 全国保険医団体連合会 : 2007年医療法改定 : 医療安全管理義務化への対応. 月間保団連 945号 : 1-53, 2007

 

2) 平成12年度厚生科学特別研究班 (主任研究員 平澤由平) : 透析医療事故の実態調査と事故対策マニュアルの策定に関する研究 (報告書), 2001

 

3) 平成16年度厚生労働科学特別研究班 (主任研究員 山崎親雄) : 「透析医療事故 (透析装置および周辺機器の故障や操作ミス関連) の実態」および「標準的透析用回路」に関する研究 (報告書), 2005

 

4) 平成18年度厚生労働科学研究 (主任研究員 北澤式文) : 「医薬品の安全管理体制の確立に関する研究 : 医薬品の安全使用のための業務手順書マニュアル」, 2007. 3 http://hodanren.doc-net.or.jp/iryoukankei/070401kaitei/iryoho/anzen.pdf

 

5) 社団法人日本臨床工学技士会医療機器管理指針策定委員会 : 「医療機器の保守点検に関する計画の策定及び保守点検の適切な実施に関する指針」Ver 1.02, 2007. 2 http://www.jacet.or.jp/topics/2007-2.pdf

 

6) 日本透析医会医療安全委員会・医療事故対策部会 (部会長 秋澤忠男) : 医療機器および医薬品の安全管理体制確保に係わる運用上の留意点 (2007年版), 2008. 4

 

P.629 掲載の参考文献

1) Jimenetz DA, Sanchez-Peya J : Standard precaution in hemodialysis? The gap between theory and practice. Nephrol Dial Transplant 14 : 823-825, 1999

 

2) 浅野泰, 秋葉隆, 日台英雄 : 透析施設における劇症肝炎発症調査報告. 透析会誌 27 (2) : 843-845, 1995

 

3) Bond WW, Favero MS, Petersen NJ, et al : Survival of hepatitis B virus after drying and storage for one week. Lancet 1 : 550, 1981

PubMed

4) Grabsch EA, BurreU LJ, Padiglione A, O'Keeffe JM : Risk of environmental and healthcare worker contamination with vancomycin-resistant enterococci during outpatient procedures and hemodialysis. Infect Control Hosp Epidemiol 27 : 287-293, 2006

 

5) 大薗英一, 栗原怜, 新谷英滋, 高橋秀実 : CDCガイドラインに基づいた透析室内感染予防対策. 日本透析医会雑誌 16 : 327-334, 2001

 

6) CDC : Recommendations for Preventing Transmission of Among Chronic Hemodialysis Patients. MMWR, 50 (RR 55), 2001

 

7) Shimokura G, Weber DJ, Miller WC, et al : Factors associated with personal protection equipment use and hand hygiene among hemodialysis staff. Am J Infect Control 34 (3) : 100-107, 2006

PubMed

8) 赤堀良恵, 須藤勉, 中野美佳, 他 : ブラッドアクセス穿刺部位の消毒方法および有効性の検討. 透析会誌 36 (10) : 1539-1544, 2003

 

9) 吉武一 : 品質保証の経緯. バリデーションと日常工程管理, pp2-9, シーエムシー, 東京, 1997

 

P.632 掲載の参考文献

1) 週刊ダイヤモンド, pp28-37, 2007. 8. 25

 

2) 伊東謙治 : 読売ウィークリー, pp24-26, 2007. 9. 9

 

3) 東京都環境局廃棄物対策部 : 2007. 1

 

4) (社) 全国産業廃棄物連合会 : 医療廃棄物適正処理推進プログラム (ADPP). 2000

 

P.636 掲載の参考文献

1) Nomoto Y, Kawaguchi Y, Kubo H, Hirano H, et al : Sclerosing encapsulating Peritonitis in patients undergoing continuous peritoneal dialysis. A report of the Japanese Sclerosing Encapsulating Peritonitis Study Group. Am J Kidney Dis 28 : 420-427, 1996

 

2) Kawanishi H, Moriishi M : Epidemiology of encapsulating Peritoneal sclerosis in Japan. Perit Dial Int 25 (suppl 4) : S14-18, 2005

 

3) Nakamoto H, Kawaguchi Y, Suzuki H : Encapsulating peritoneal sclerosis in patients undergoing continuous ambulatory peritoneal dialysis in Japan. Adv Perit Dial 18 : 119-123, 2002

PubMed

4) Kawaguchi Y, Saito A, Kawanishi H, Nakayama M, et al : Recommendations on the management of encapsulating Peritoneal sclerosis in Japan, 2005 : diagnosis, predictive markers, treatment, and preventive measures. Perit Dial Int 25 (suppl 4) : S83-95, 2005

 

5) Honda K, Oda H : Pathology of encapsulating peritoneal sclerosis. Perit Dial Int 25 (suppl 4) : S19-29, 2005

 

6) 川西秀樹他 : 被嚢性腹膜硬化症 (encapsulating peritoneal sclerosis : EPS) に対する治療戦略腎と透析 51 別冊腹膜透析 2001 : 36-38, 2001

 

7) Kawanishi H, Kawaguchi Y, Fukui H, Hara S, et al : Encapsulating Peritoneal sclerosis in Japan : a prospective, controlled, multicenter study. Am J Kidney Dis 44 : 729-737, 2004

PubMed

8) Kawanishi H, Moriishi M : Encapsulating peritoneal sclerosis : Prevention and treatment. Perit Dial Int 27 (suppl 2) : S289-292, 2007

 

血液浄化のトピックス

P.645 掲載の参考文献

1) 血液浄化関連標準化検討委員会WG2 (透析液関連) : 透析液清浄化ガイドライン Ver. 1.05. 日本臨床工学技士会, 2006

 

2) 秋葉隆, 川西秀樹, 峰島三千男, 政金生人, 他 : 透析液水質基準と血液浄化器性能評価基準 2008. 透析会誌 41 : 159-167, 2008 注 : 透析会誌 41 : 457-459, 2008に修正・補足記事あり.

 

3) 日本透析医学会統計調査委員会 : わが国の透析療法の現況 (2006年12月31日現在). 日本透析医学会, 2007

 

P.650 掲載の参考文献

1) Humes HD, Fissell WH, Tiranathanagul K : The future of hemodialysis membranes. Kidney Int 69 : 1115-1119, 2006

PubMed

2) Shin M, Matsuda K, Ishii O, Terai H, et al : Endothelialized networks with a vascular geometry in microfabricated poly (dimethyl siloxane). Biomed Microdevices 6 : 269-278, 2004

PubMed

3) Gock H, Salvaris E, Han W, Murray-Segal L, et al : Anti-alpha 1, 3-galactose-mediated hyperacute rejection of vascuiarized transplantation in a small animal model. Transplant Proc 37 : 2075, 2000

 

4) Kozlowski T, Ierino FL, Lambrigts D, Foley A, et al : Depletion of anti-Gal (alpha) 1-3Gal antibody in baboons by specific alpha-Gal immunoaffinity columns. Xenotransplantation 5 : 122-131, 1998

PubMed

5) Zhong R, Luo Y, Yang H, Garcia B, et al : Improvement in human decay accelerating factor transgenic porcine kidney xenograft rejection with intravenous administration of gas914, a polymeric form of alphaGAL. Transplantation 75 : 10-19, 2003

PubMed

6) Lai L, Kolber-Simonds D, Park KW, Cheong HT, et al : Production of alpha-1, 3-galactosyltransferase knockout pigs by nuclear transfer cloning. Science 295 : 1089-1092, 2002

PubMed

7) Yamada K, Yazawa K. Shimizu A, Iwanaga T, et al : Marked prolongation of porcine renal xenograft survival in baboons through the use of alpha 1,3-galactosyltransferase gene-knockout donors and the cotransplantation of vascularized thymic tissue. Nat Med 11 : 32-34, 2005

PubMed

8) Soin B, Smith KG, Zaidi A, Cozzi E, et al : Physiological aspects of pig-to-primate renal xenotransplantation. Kidney Int 60 : 1592-1597, 2001

PubMed

9) Butler D : Last chance to stop and think on risks of xenotransplants. Nature 391 : 320-324, 1998

PubMed

10) Yokoo T, Kawamura T, Kobayashi E : Kidney organogenesis and regeneration : a new era in the treatment of chronic renal failure? Clin Exp Nephrol 12 : 326-331, 2008

PubMed

11) Dekel B, Amariglio N, Kaminski N, Schwartz A, et al : Engraftment and differentiation of human metanephroi into functional mature nephrons after transplantation into mice is accompanied by a profile of gene expression similar to normal human kidney development. J Am Soc Nephrol 13 : 977-990. 2002

PubMed

12) Rookmaaker MB, Tolboom H, Goldschmeding R, Zwaginga JJ, et al : Bone-marrow-derived cells contribute to endothelial repair after thrombotic microangiopathy. Blood 99 : 1095, 2002

PubMed

13) Lanza RP, Chung HY, Yoo JJ, Wettstein PJ, et al : Generation of histocompatible tissues using nuclear transplantation. Nat Biotechnol 20 : 689-696, 2002

PubMed

14) Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, et al : Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol 26 : 101-106, 2008

PubMed

15) Saito A. Pietromonaco S. Loo AK, Farquhar MG : Complete cloning and sequencng of rat gp330/"megalin" a distinctive member of the low density lipoprotein receptor gene family. Proc Natl Acad Sci USA 91 : 9725-9729, 1994

 

16) Saito A, Kazama JJ, Iino N, Cho K, et al : Bioengineered implantation of megalin-expressing cells : a potential intracorporeal therapeutic model for uremic toxin protein clearance in renal failure. J Am Soc Nephrol 14 : 2025-2032, 2003

 

17) Maruyama H, Sugawa M, Moriguchi Y, Imazeki I, et al : Continuous erythropoietin delivery by muscle-targeted gene transfer using in vivo electroporation. Hum Gene Ther 11 : 429-437, 2000

PubMed

P.658 掲載の参考文献

1) 吉田文武, 酒井清孝 : 化学工学と人工臓器, 第2版, 共立出版, 東京, 1997

 

2) Sakai K : Determination of pore size and pore size distribution 2. Dialysis membranes. Journal of Membrane Science 96 : 91-130, 1993

 

3) Colton CK, Lowrie EG : Hemodialysis : Physical principles and technical considerations. The Kidney, Brenner BM, Rector Jr FC (eds), 2nd ed, vol 2, pp2425-2489, WB Saunders, Philadelphia, 1981

 

4) Babb AL, Popovich RP, Christopher TG, Scribner BH : The genesis of the square meter-hour hypothesis. Trans Am Soc Artif Intern Organs 17 : 81-91, 1971

PubMed

5) Dellanna F, Wuepper A, Baldamus CA : Internal filtration-advantage in haemodialysis? Nephrol Dial Transplant 11 (suppl 2) 183-86, 1996

 

P.663 掲載の参考文献

1) 川西秀樹 : PD+HD療法の適応と問題点. 透析ケア 7 : 50-55, 2001

 

2) Paniagua R, Amato D, Vonesh E, Correa-Rotter R, et al : Mexican Nephrology Collaborative Study Group : Effects of increased peritoneal clearance on mortality rates in peritoneal dialysis : ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 13 : 1307-1320, 2002

 

3) Lo WK, Ho YW, Li CS, et al : Effect of Kt/V on survival and clinical outcomes in a randomized prospective study. Kidney Int 64 : 649-656, 2002

 

4) Fukui H, Hara S, Hashimoto Y, Horiuchi T, et al : PD+HD Combination Therapy Study Group : Review of combination of peritoneal dialysis and hemodialysis as amodality of treatment for end-stage renal disease. Ther Apher Dial 8 : 56-61, 2004

 

5) Lam MF, Tang C, Wong AK, Tong KL, et al : A prospective study of adequacy in Asian patients on long term, small volume, continuous ambulatory peritoneal dialysis. Perit Dial Int 26 : 466-474, 2006

PubMed

6) Lo WK, Ho YW, Li CS, et al : Effect of Kt/V on survival and clinical outcomes in a randomized prospective study. Kidney Int 64 : 649-656, 2002

 

7) Kawanishi H, Hashimoto Y, Nakamoto H, Nakayama M, Tranaeus A : Combination therapy with peritoneal dialysis and hemodialysis. Perit Dial Int 26 : 150-154, 2006

PubMed

8) Nakamoto H, Takane H, Sugahara S, Kanno Y, Okada H, Yamamoto T, Suzuki H : Longitudinal changes of peritoneal function calculated by PDC test in patient after long-term CAPD. Adv Perit Dial 19 : 97-102, 2003

 

P.669 掲載の参考文献

1) Saito A : Kidney tissue engineering. Tissue Engineering using Ceramics and Polymers, Boccaccini AR, Gough JE (eds), pp 421-444, Woodhead Publishing Limited, Cambridge, 2007

 

2) Ueda H, Watanabe J, Konno T, Takai M, et al : Asymmetrically functional surface properties on biocompatible phospholipid polymer membrane for bioartificial kidney. Published online 12 December 2005 in Wiley InterScience (www.interscience.wiley.com). DOI : 10.1002/jbm.a.30606

 

3) Duc VM, Yokoyama TA, Sawada K, Inagaki M, et al : Enhancement of permeability in endothelial cells for the development of an antithrombogenic bioartificial henofilter. Biotech Bioeng 101 : 634-641, 2008

 

4) Humes HD, Weitzel WF, Bartlett RH. Swaniker FC, et al : Initial clinical results of the bioartificial kidney containing human cells in ICU patients with acute renal failure. Kidney Int 66 : 1578-1588, 2004

PubMed

5) Inagaki M, Yokoyama TA, Sawada K, Duc VC, et al : Prevention of LLC-PK, cell overgrowth in a bioartificial renal tubule device using a MEK inhibitor, U0126. JBiotechnol l32 : 57-64, 2007

 

P.673 掲載の参考文献

1) Stange J, Mitzner S, Ramlow W, et al : A new procedure for the removal of protein bound drugs and toxins. ASAIO J 39 : M621-625, 1993

PubMed

2) 児玉敏宏, 北裕次, 上田俊郎, 他 : 持続的アルブミン純化システムの実験的検討. 透析会誌 32 : 1127-1133, 1999

 

3) 阿部貴弥, 川嶋隆久, 篠崎真紀, 他 : MARS(R) (molecular adsorbent recirculating system) の基礎的側面-Extracorporeal Albumin Dialysisの観点から-. 日本アフェレシス学会雑誌 24 : 223-227, 2005

 

4) Laleman W, Wilmer A, Evenepoel P, et al : Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit Care 10 : R108, 2006

PubMed

5) Greco AV, Mingrone G, Favuzzi A, et al : Subclinical hepatic encephalopathy : role of tryptophan binding to albumin and the competition with indole-3-acetic acid. J Invest Med 48 : 274-280, 2000

 

6) Hassanein T, Oliver D, Stang J, Steiner C : Albumin dialysis in cirrhosis with superimposed acute liver injury : possible impact of albumin dialysis on hospitalization costs. Liver Int 23 (S-3) : 61-65, 2003

 

7) Pares A, Cisneros L, Salmer6n JM, et al : Extracorporeal albumin dialysis : aprocedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 99 : 1105-1110, 2004

 

P.677 掲載の参考文献

1) Zucchelli P : Hemodialysis-induced symptomatic hypotention. A review of pathophysiological mechanisms, Int J Artif Organs 10 (3) : 139-144, 1987

 

2) Mitch WE, Price SR : Mecanisms activated by kidney disease and loss of muscle mass. Am J Kidney Dis 38 : 1337-1342, 2001

 

3) 斎藤明, 秋澤忠男, 佐藤隆, 他 : 酢酸フリー透析剤SZ-D21 多施設共同比較臨床試験 (第III相試験). 診療と新薬 44 : 12-30, 2007

 

4) 日本透析医学会統計調査委員会編 : わが国の慢性透析療法の現況 (2004年12月31日現在).

 

5) 久野勉, 友雅司, 青地郁夫 : 「酢酸フリー」透析剤カーボスター(R) のもたらす臨床効果と課題. Pharma Media 26 (7) : 63-68, 2008

 

6) Movilli E, Camirini C, Zein H, et al : A prospective comparison of bicarbonate dialysis hemodiafiltration, and acetate-free biofiltration in the elderly. Am J Kindey Dis 35 : 493-499, 2000

 

7) Tonelli M, Dymond C, Gourishankar S, et al : Extended reuse of polysulfone hemodialysis membranes using citric acid and heat. ASAIO J 50 : 98-101 : 2004

PubMed

P.683 掲載の参考文献

1) 永渕弘之, 三浦健一郎, 縄田寛, 他 : 小児への急性血液浄化療法の適用と効果. ICUとCCU 28 : S48-S50, 2004

 

2) 太田稔, 嶋村剛, 陳孟鳳, 他 : 劇症肝炎に対するアフェレシスの役割 : 生体肝移植との関わり. 医工学治療 16 : 26-31, 2004

 

3) 土濃塚広樹, 久木田和丘, 米川元樹, 他 : ICUにおける個人用HDF装置NDF-21の操作性および有用性の検討. ICUとCCU 30 : S110-S111, 2006

Medical*Online

4) 小野淳一, 斎尾英俊, 佐々木真理, 他 : 血液浄化量の増加を目的とした持続的透析液供給システムの開発. ICUとCCU 32 : S162-S165, 2008

 

5) 松山法道, 笠岡俊志, 森岡明子, 他 : ろ過型人工腎臓用補液ダブルバッグ製剤の有用性について. 腎と透析 58 : 499-502, 2005

 

P.688 掲載の参考文献

1) Casino FG, Lopez T : The equivalent renal urea clearance : anew parameter to assess dialysis dose. Nephrol Dial Transplant 11 : 1574-1581, 1996

 

2) Cole L, Bellomo R, Davenport P, Balddwin I, et al : high-volume hemofiltration in human septic shock. Int Care Med 27 : 978-986, 2001

 

3) 小野淳一, 横田喜美夫, 石川純子, 他 : Continuous renal replacement therapyとしてのHigh volume continuous hemodialysisの意義. ICUとCCU 26 (別冊号) : S72-S74, 2002

 

4) Ronco C, Bellomo R, Homel P, et al : Effects of different dose in continuous veno-venous haemofiltration on outcomes of acute renal failure : prospective randomized trial. Lancet 356 : 26-30, 2000

PubMed

5) Saudan P, Niederberger M, De Seigneux S, et al : Adding a dialysis dose to continuous hemofiltration increase survival in patients with acute renal failure. Kidney Int 70 : 1312-1317, 2006

PubMed

6) VA/NIH Acute Renal Failure Trial Network : Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 359 : 7-20, 2008

PubMed

P.691 掲載の参考文献

1) Okazaki T, et al : Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 9 : 1477-1483, 2003

PubMed

2) Jahns R, et al : Direct evidence for a beta 1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest 113 : 1419-1429, 2004

PubMed

3) Wallukat G, et al : Removal of autoantibodies in dilated cardiomyopathy by immunoadsorption. Int J Cardiol 54 : 191-195. 1996

PubMed

4) Baba A. Autoantigen estimation and simple screening assay against cardiodepressant autoantibodies in patients with dilated cardiomyopathy. Ther Apher Dial 12 : 109-116, 2008

PubMed

5) 馬場彰泰, 他 : 拡張型心筋症患者の免疫吸着療法に有効な吸着カラムの同定. 日本アフェレシス学会雑誌 23 : 101-102, 2004

 

P.697 掲載の参考文献

1) Hausfater P, Cacoub P, Assogba U, Lebon P, et al : Plasma exchange and interferon-alpha pharmacokinetics in patients with hepatitis C virus-associated systemic vasculitis. Nephron 91 (4) : 627-630, 2002

PubMed

2) Ramratnam B, Bonhoeffer S, Binley J, et al : Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet 354 (9192) : 1782-1785, 1999

PubMed

3) Schettler V. Monazahian M, Wieland E, Thomssen R, et al : Effect of heparin-induced extracorporeal low-density lipoprotein precipitation (HELP) apheresis on hepatitis C plasma virus load. Ther Apher 5 (5) : 384-386, 2001

PubMed

4) Sawada K, Malchesky PS, Nose Y : Available Removal Systems : State of the Art. Curr Stud Hematol Blood Transfus 57 : 51-113, 1990

PubMed

5) Yamashita T, Arai K, Sakai A, Mizukoshi E, et al : Virological effects and safety of combined double filtration plasmapheresis (DFPP) and interferon therapy in patients with chronic hepatitis C : A preliminary study. Hepatol Res 36 (3) : 167-175, 2006

PubMed

6) Fujiwara K, Kaneko S, Kakumu S, Sata M, et al : Double filtration plasmapheresis and interferon combination therapy for chronic hepatitis C patients with genotype 1 and high viral load. Hepatol Res 37 (9) : 701-710, 2007

PubMed

7) Okuda K, Yokosuka O : Natural history of chronic hepatitis C in patients on hemodialysis : case control study with 4-23 years of follow-up. World J Gastroenterol 10 (15) : 2209-2212, 2004

PubMed

8) Ishida H, Tanabe K, Tokumoto T, et al : Hepatitis C virus decreases in patients with maintenance hemofiltration therapy. Artif Organs 28 (3) : 316-318, 2004

PubMed

9) Sawada K, Ohnishi K, Fukunaga K, Shimoyama T : A new treatment for HCV-ulcerative colitis comorbidity intolerant to INF-alpha. Am J Gastroenterol 98 (1) : 228-229, 2003

PubMed

10) Sawada K, Ohnishi K, Kusaka T, Matoba Y, et al : Dramatic response to granulocytapheresis in a Crohn's disease case complicated by hepatitis C virus. Dig Dis Sci 50 (8) : 1533-1534, 2005

 

11) Sawada K, Kashiwamura S, Okamura H, Ohnishi K et al : Selective Granulocyte and Monocyte Apheresis as a New Adjunct to Enhance the Efficacy of Interferonalpha+Ribavirin in Patients with High Plasma Hepatitis C Virus. Diges Liver Dis 37 (7) : 515-521, 2005

 

12) Moriyama M, Kaneko M, Matsumura H. Fukushima A, et al : Removal of hepatitis C virus by G-1 beads in sera from patients with chronic hepatitis C. Intervirology 48 (2-3) : 84-88, 2005

 

13) Sawada K, Ohnishi K, Fukunaga K, Kusaka T, et al : Granulocyte and Monocyte Adsorptive Apheresis for Patients with Chronic Hepatitis C Virus Infection : A report on six cases with high plasma viremia. Ther Apher Dial 7 (6) : 547-553, 2003

PubMed

14) Sawada K, Masaki N, Hayashi S, Zeniya M, et al : Immunomodulatory Effect of Selective Leucocyte Depletion as a New Adjunct to Interferon-α2b plus Ribavirin Therapy : A Pilot Study in Patients with High Plasma HCV Viraemia. J Viral Hepat 12 (3) : 274-282, 2005

 

15) Cornish AL, Chong MM, Davey GM, et al : Suppressor of cytokine signaling-1 regulates signaling in response to interleukin-2 and other gamma c-dependent cytokines in peripheral T cells. J Biol Chem 278 : 22755-22761, 2003

 

P.703 掲載の参考文献

1) 松尾秀徳, 後藤公文, 近藤誉之, 他 : 神経疾患に対する白血球系細胞除去療法 : 選択的に病因となるリンパ球を除去する試み. 日アフェレシス会誌 24 : 157-166, 2005

 

2) Onodera H, Ninomiya K, Yoshida M, et al : Development of a device for selective removal of CD4+ T cells. Ther Apher Dial 7 : 329-333, 2003

PubMed

3) Matsuo H, Goto H, Kambara C, et al : Selective adsorption of human CD4+ T cells. Ther Apher Dial 8 : 194-196, 2004

PubMed

4) Sakaguchi S : Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22 : 531-536, 2004

PubMed

5) Illes Z, Kondo T, Yokoyama K, et al : Identification of autoimmune T cells among in vivo expanded CD25+ T cells in multiple sclerosis. J Immunol 162 : 1811-1817. 1999

PubMed

P.708 掲載の参考文献

1) Mori T, Eguchi Y, Shimizu T, Endo Y, et al : A case of acute hepatic insufficiency treated with novel plasmapheresis plasma diafiltration for bridge use until liver transplantation. Ther Apher 6 : 463-466, 2002

PubMed

2) Saotome T, Endo Y, Sasaki T, Tabata T, et al : A case of severe acute pancreatitis treated with CTR-001 direct hemoperfusion for cytokine apheresis. Ther Apher Dial 9 : 367-371, 2005

 

3) Oda S, Hirasawa H, Shiga H, Nakanishi K. et al : Cytokine adsorptive property of various adsorbents in immunoadsorption columns and a newly developed adsorbent : an in vitro study. Blood Purif 22 : 530-536, 2004

 

4) Kobe Y, Oda S, Matsuda K, Nakamura M, et al : Direct hemoperfusion with a cytokine-adsorbing device for the treatment of persistent or severe hypercytokinemia : a pilot study. Blood Purif 25 : 446-453, 2007

PubMed

5) 清水智治, 花澤一芳, 佐藤浩一, 梅木雅彦, 他 : 下部消化管穿孔術後敗血症に対するPMX治療の有用性に関する検討. 日本外科感染症学会雑誌 4 : 189-195, 2007

Medical*Online

6) Haase M, Silvester W, Uchino S, Goldsmith D, et al : A pilot study of high-adsorption hemofiltration in human septic shock. Int J Artif Organs 30 : 108-117, 2007

 

7) Weber V. Hartmann J, Linsberger I, Falkenhagen D : Efficient adsorption of tumor necrosis factor with an in vitro set-up of the microspheres-based detoxification system. Blood Purif 25 : 169-174, 2007

 

8) Sandeman SR, Howell CA, Mikhalovsky SV, Phillips GJ, et al : Inflammatory cytokine removal by an activated carbon device in a flowing system. Biomaterials 29 : 1638-1644, 2008

 

P.714 掲載の参考文献

1) Todd JK : Toxic shock syndrome. Clin Microviol Rev 1 : 432-446, 1988

PubMed

2) Azuma K, Koike K, Kobayashi T, et al : Detection of ciruulating superantigens in an intensive care unit population. Int J Infec Dis 8 : 292-298, 2004

 

3) Miwa K, Fukuyama M, Ida N, et al : Preparation of a superantigen-adsorbing device and its superantigen removal efficacies in vitro and in vivo. Int J Infect Dis 7 : 21-28, 2003

PubMed

4) Darwick L, Balasch M, Plana-Duran J, et al : Cytokine profiies of peripheral blood mononuclear cells from pigs with postweaning multisystemic wasting syndrome in response to mitogen, superantigen or recall viral antigens. J Gen Virol 84 : 3453-3457, 2003

PubMed

5) Miwa K, Fukuyama M, Ida N, et al : Preparation of a superantigen-adsorbing device and its superantigen removal efficacies in vitro and in vivo. Int J Infect Dis 7 : 21-28, 2003

PubMed

6) 三和敬史, 柴山尚子, 河邊香拓, 他 : グラム陽性菌敗血症に対する新しい血液浄化法-スーパー抗原吸着カラム-. 日本アフェレーシス学会雑誌 24 : 244-249, 2005

 

7) Fenwick P, Ryan C, Sriskandan S, et al : Application of a rat model of streptococcal shock to evaluate on-line hemoperfusion and removal of circulating superantigens. Crit Care Med 31 : 171-178, 2003

PubMed

8) 池田寿昭, 福山真弓, 三和敬史, 他 : 敗血症性ARDSを合併した頸部膿瘍症例におけるTSST-1抗原の検討. 日救急医学会誌 13 : 67-72, 2002

 

9) 池田寿昭, 池田一美, 鈴木秀道, 他 : 大動物におけるTSST-1投与実験モデルに関する研究-呼吸, 循環からの検討-. 日救急医学会誌 11 : 289-290, 2000

 

P.717 掲載の参考文献

1) Nakada T, Oda S, Matsuda K, Sadahiro T, et al : Continuous hemodiafiltration with PMMA Hemofilter in the treatment of patients with septic shock. Mol Med 14 : 257-263, 2008

PubMed

2) 辻本広紀, 小野聡, 木下学, 望月英隆 : SepsisにおけるCD16陽性単球の特徴. 日外感染症会誌 4 : 197-202, 2007

 

3) 阿部信二 : 急性肺傷害に対するPMX療法. ICUとCCU 32 (suppl) : S26, 2008

 

4) Saotome T, Endo Y, Sasaki T, Tabata T, et al : A case of severe acute pancreatitis treated with CTR-001 direct hemoperfusion for cytokine apheresis. Ther Apher 9 : 367-371, 2005

 

5) Kobe Y, Oda S, Matsuda K, Nakamura M, et al : Direct hemoperfusion with a cytokine-adsorbing device for the treatment of persistent or severe hypercytokinemia. Blood Purif 25 : 446-453, 2007

PubMed

6) 岩坂日出男 : HMGB1を標的とした血液浄化療法の可能性. ICUとCCU 32 (suppl) : S16, 2008

 

P.721 掲載の参考文献

1) 遠藤善裕, 清水智治, 谷徹 : 本邦における稀少症例に対するアフェレシスに関するアンケート調査の集計結果. 日本アフェレシス学会誌 27 (2) : 171-177, 2008

 

2) 難病情報センター, http://www.nanbyou.or.jp/top.html

 

3) Atsumi T, Kato K, Kurosawa S, et al : A case of Crow-Fukase syndrome with elevated soluble interleukin-6 receptor in cerebrospinal fluid. Response to double-filtration plasmapheresis and corticosteroids. Acta Haematol 94 : 90-94, 1995

PubMed

4) 津田裕士, 谷口修, 杢野千穂, 他 : 抗カルジオリピン抗体吸着への試み 応用. 人工臓器 18 : 7-10, 1989

 

P.724 掲載の参考文献

1) Bannon L : Computer supported cooperative work (CSCW) initial exploration. Scandinavian Journal of Information Systems 5 : 3-24, 1993

 

2) Kyng M : Designing for cooperation. Communications of the ACM 34 (12) : 65-73, 1991

 

3) Peter HC, Kjeld S ; 伊藤謙治訳 : コンピュータ支援の強調作業とグループウェア. 人間工学ハンドブック, 伊藤謙治, 桑野園子, 小松原明哲編, pp619-636, 朝倉書店, 東京, 2003

 

4) 鈴木聡, 宮尾眞輝, 金子岩和, 他 : 経営工学手法を用いた血液浄化業務の高効率化と安全確保. 医工学治療 14 (3) : 151-156, 2002

 

P.728 掲載の参考文献

1) 厚生省五十年史編集委員会編 : 1988a「厚生省五十年史 (記述編)」, 財団法人厚生問題研究会

 

2) 厚生省五十年史編集委員会編 : 1988b「厚生省五十年史 (資料編)」, 財団法人厚生問題研究会

 

3) 川口良人 : わが国における腎不全治療のあゆみ 透析治療と腎移植. 日内会誌 91 : 94-103, 2002

 

4) 社会保険・老人保健診療報酬「医科点数表の解釈」平成18年4月版, 社会保険研究所

 

5) 改定診療報酬点数表参考資料 (平成20年4月1日実施), 日本医師会

 

6) わが国の慢性透析療法の現況. 日本透析医学会

 

P.733 掲載の参考文献

1) 社会保険研究所 : 診断群分類点数表. DPC改正点の解説, 2008

 

2) 日本透析医学会統計調査委員会 : わが国の慢性透析療法の現況, 2007

 

P.737 掲載の参考文献

1) 大平整爾 : 患者の年齢・背景に応じたインフォームド・コンセント. 透析療法の合併症対策ハンドブック, 秋澤忠男編, pp34-45, 先端医学社, 東京, 2005

 

2) Appelbaum PS : Clinical Practice Assessment of patients' competence to consent to treatment. N Engl J Med 357 : 1834-1840, 2007

PubMed

3) 大平整爾, 辻寧重, 伊丹儀友 : 痴呆患者の透析療法導入の可否と留意点. 臨牀透析 17 : 1177-1186, 2001

 

4) Galla JH : Clinical practice guideline on shared decision-making in the appropriate initiation of and withdrawal from dialysis. J Am Soc Nephrol 11 : 1340-1342, 2000

PubMed

5) 加藤尚武 : Bioethicsから生命倫理学へ, 生命倫理学を学ぶ人のために, 世界思想社, 東京, 1998

 

薬物投与

P.745 掲載の参考文献

1) Inoue T, Shibahara N, Miyagawa K, Itahana R, et al : Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure. Clin Nephrol 60 : 90-95, 2003

PubMed

2) Hung SI, Chung WH, Liou LB, Chu CC, et al : HLA-B* 5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinoL Proc Natl Acad Sci USA 102 : 4134-4139, 2005

PubMed

3) Martin U, Temple RM, Winney RJ, Prescott LF : The disposition of paracetamol and the accumulation of its glucuronide and sulphate conjugates during multiple dosing in patients with chronic renal failure. Eur J Clin Pharmacol 41 : 43-46, 1991

PubMed

4) Prescott LF, Speirs GC, Critchley JA, Temple RM, et al : Paracetamol disposition and metabolite kinetics in patients with chronic renal failure. Eur J Clin Pharmacol 36 : 291-297, 1989

PubMed

5) 平田純生 : 薬物中毒における血液浄化法の薬物動態的評価. 中毒研究 21 : 105-113, 2008

 

書評を投稿する